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Genomic Instability and the Oncohistone H3K27M Drive Gliomagenesis in a
Murine Model
Abstract
Maintaining genome stability is crucial for human health and it is of particular importance in neural cells
during early brain development. Genome maintenance occurs at two broad stages; surveillance during
DNA replication and DNA damage repair in differentiating and mature cells. Neural cells are particularly
sensitive to DNA strand breaks and defective DNA damage responses can result in detrimental effects on
the nervous system, including cancer. Multiple DNA repair pathways play critical roles in preventing DNA
damage accumulation in stem and neural progenitor cells. The mechanisms that protect progenitor
genomes also suppress DNA mutations that can result in cancer. A primary objective of this dissertation
is to understand the relative contributions of key DNA repair factors that prevent tumorigenesis during
cortical development. We have compared the differential effects of inhibition of homologous
recombination (HR), via BRCA2-inactivation and non-homologous end-joining (NHEJ), via
LIG4-inactivation towards tumorigenesis by directing their deletion specifically to early cortical
progenitors using an Emx1-cre recombinase driver. We find that coincident loss of either of these repair
pathways with p53 inhibition result in distinct high-grade glioma (HGG) formation resulting from elevated
genome instability by DNA damage accumulation during embryogenesis. Furthermore, the presence of
the oncohistone H3K27M mutation, commonly found in pediatric HGGs, enhances genome instability and
accelerates cortical gliomagenesis with p53 inactivation and defective HR or NHEJ. Additionally, the
H3K27M resultant gliomas showed distinctive differences in increased brain tumor penetrance and
diffusion. Through RNA-sequencing and whole exome sequencing we identify upregulation of genes
normally controlled by bivalent gene promoter post-translational modifications, which result in
transcriptional alterations in genes important for both neural development and tumorigenesis.
Mechanistically, this is done by targeting specific populations of cortical cells that are more susceptible
to DNA damage and transformations that may cause additional critical mutations during a limited
timeframe of early cortical development which eventually result in HGGs. We provide evidence supporting
that BRCA2 functions to provide DSBR and genome stability to the early-born proliferating cortical
progenitor cell population, while LIG4 provides the same function but to a lesser extent to progenitor cells
and more so to post-mitotic neurons. Since, epigenetic regulation is tightly connected with neural
development and differentiation, we propose the specific genes that H3K27M effects may differ
depending on the time period and particular cell state from which the HGG initiates. We believe this
contributes to reduced heterogeneity in glioma expression signatures with H3K27M in addition to either
HR- or NHEJ-deficiency. Ultimately this work highlights the power of inducible genetically engineered
mouse models as an approach to better understand the complexities of providing a connection between
genome instability and gliomagenesis.
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ABSTRACT
Maintaining genome stability is crucial for human health and it is of particular
importance in neural cells during early brain development. Genome maintenance occurs
at two broad stages; surveillance during DNA replication and DNA damage repair in
differentiating and mature cells. Neural cells are particularly sensitive to DNA strand
breaks and defective DNA damage responses can result in detrimental effects on the
nervous system, including cancer. Multiple DNA repair pathways play critical roles in
preventing DNA damage accumulation in stem and neural progenitor cells. The
mechanisms that protect progenitor genomes also suppress DNA mutations that can result
in cancer. A primary objective of this dissertation is to understand the relative
contributions of key DNA repair factors that prevent tumorigenesis during cortical
development. We have compared the differential effects of inhibition of homologous
recombination (HR), via BRCA2-inactivation and non-homologous end-joining (NHEJ),
via LIG4-inactivation towards tumorigenesis by directing their deletion specifically to
early cortical progenitors using an Emx1-cre recombinase driver. We find that coincident
loss of either of these repair pathways with p53 inhibition result in distinct high-grade
glioma (HGG) formation resulting from elevated genome instability by DNA damage
accumulation during embryogenesis. Furthermore, the presence of the oncohistone
H3K27M mutation, commonly found in pediatric HGGs, enhances genome instability
and accelerates cortical gliomagenesis with p53 inactivation and defective HR or NHEJ.
Additionally, the H3K27M resultant gliomas showed distinctive differences in increased
brain tumor penetrance and diffusion. Through RNA-sequencing and whole exome
sequencing we identify upregulation of genes normally controlled by bivalent gene
promoter post-translational modifications, which result in transcriptional alterations in
genes important for both neural development and tumorigenesis. Mechanistically, this is
done by targeting specific populations of cortical cells that are more susceptible to DNA
damage and transformations that may cause additional critical mutations during a limited
timeframe of early cortical development which eventually result in HGGs. We provide
evidence supporting that BRCA2 functions to provide DSBR and genome stability to the
early-born proliferating cortical progenitor cell population, while LIG4 provides the same
function but to a lesser extent to progenitor cells and more so to post-mitotic neurons.
Since, epigenetic regulation is tightly connected with neural development and
differentiation, we propose the specific genes that H3K27M effects may differ depending
on the time period and particular cell state from which the HGG initiates. We believe this
contributes to reduced heterogeneity in glioma expression signatures with H3K27M in
addition to either HR- or NHEJ-deficiency. Ultimately this work highlights the power of
inducible genetically engineered mouse models as an approach to better understand the
complexities of providing a connection between genome instability and gliomagenesis.
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CHAPTER 1.

INTRODUCTION

Introductory Comments
Cancer is a multifaceted disease, with two of the most important contributing
etiologic factors being genetic and epigenetic alterations. Over the last half century most
of the focus has been on understanding the genetic side, searching for abnormal genes
causing the development of human cancer. In particular, gene mutations influencing
DNA repair, cell cycle regulators and cell-death pathways were found to be major genetic
causes of malignancies [1]. The meaning of epigenetics has evolved over time but now
more than ever an appreciation for epigenetic mechanisms are critical for our
understanding of how regulation of gene expression effects cancer development.
Advances in sequencing technology have been instrumental in allowing us to further
examine the connections between genetic mutations and epigenetic alterations in cancer.
Even with a better understanding of cancer in today’s world one of the most frustrating
aspects is still its unpredictability. Although it is true that cancer predominantly affects
the elderly, mostly due to the accumulation of mutations over an entire lifetime, therefore
it is especially surprising and emotionally difficult when it befalls in children. Thankfully
pediatric cancer is scarce and pediatric brain tumors, which can be extremely detrimental,
are some of the rarest [2]. Together, this dissertation presents a cumulation of work which
hopes to provide further understanding of the genetic and epigenetic alterations and their
roles in pediatric brain tumor development.
DNA Double Strand Break Repair During Cortical Development
Maintenance of genome stability is vital for human health and it is of particular
importance in neural cells during early brain development. Genome stability is regulated
by multiple DNA repair pathways that work simultaneously to ensure the integrity of
DNA and defects in DNA repair can result in the development of devastating diseases,
many affecting the nervous system or cancer. Table 1-1 summarizes various DNA
damage response signaling pathways and associated neuropathologies resulting from
disruption of genome stability [3, 4]. These pathways include nucleotide excision repair
(NER), mismatch repair (MMR), base excision repair (BER)/single strand break repair
(SSBR) or double strand break repair (DSBR), which are critical in maintaining the
integrity of the genome [4, 5]. DNA double strand breaks (DSBs) are the most deleterious
form of DNA damage in neural cells but are repaired primarily through homologous
recombination (HR) in replicating stem/progenitor cells and nonhomologous end-joining
(NHEJ) in non-replicating, differentiating cells [6, 7]. A major source of endogenous
DSBs come from replicative stress in the proliferating progenitors of the neocortex
during early brain development [3]. The complex process of cortical development begins
around six weeks after conception in humans with neurogenesis lasting until about week
18 [8]. After neurogenesis the requirements for genome maintenance markedly change in
the transition to nervous system maturation. The genomes of differentiated and mature
neural cells, which occupy the cortex for the rest of the its life, need to be protected
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Table 1-1.

DNA repair pathways and disruptions resulting in neuropathology.

DNA Repair Pathway
Homologous
recombination (HR)

Main Components
DNA Damage
ATM, ATR, MRN, Double strand breaks
BRCA1/2, XRCC2,
Rad51/54, RPA,
LIG1
ATM, ATR,
Ku70/ 80, 53BP1,
DNA-PKcs, XLF,
Artemis, XRCC4,
LIG4
PARP1, MRN,
CtIP, LIG1/3

Neuropathology
Neurodevelopmental
defects/microcephaly
Brain tumors

Base excision repair

XRCC1, DNA
Polβ, PARP1, APE

Single strand breaks

Neurodegeneration

Fanconi anemia/
Homologous
recombination

19 FANC proteins

DNA cross-links

Brain tumors
Neurodevelopmental
defects/microcephaly

Nucleotide excision repair
Transcription coupled
repair

XPC, PCNA, RPA,
LIG1/3

Bulky adducts/
Helix-distorting lesions

Neurodegeneration
Complex

Mismatch repair

MSH2/3/6, MLH1,
POLD, LIG1

Misincorporated bases
(during replication)

Brain tumors

MRE11/RAD50/NBS1
complex
Ataxia telangiectasia,
mutated (ATM)

MRN, ATM

Defective DNA damage Microcephaly
signaling (double strand Neurodegeneration
break signaling)

Ataxia telangiectasia and
Rad3-realted (ATR)

ATR

Replication stress

Non-homologous endjoining (NHEJ)
(canonical )
Alternative-NHEJ

Neurodevelopmental
defects/microcephaly

Modified with permission from Springer Nature. McKinnon, P.J., Maintaining genome stability
in the nervous system. Nat Neurosci, 2013. 16(11): p. 1523-9.
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against DNA damage [3, 4]. Damage in these cells results mainly from reactive oxygen
species or transcriptional disruption breaks [9, 10]. Hence, throughout development and
maintenance of the nervous system, especially the cerebral cortex, there is a perpetual
need to ensure genome integrity. The human cortex is an extremely complex and
important region of the brain where even minor errors in DNA repair resulting in
damaged cortical cells can be particularly detrimental [11]. Providing that the machinery
for apoptosis is functional in cells that are unable to repair DSBs, p53-mediated apoptosis
is the preferred pathway for DNA damage response (DDR) in cortical progenitors to
eliminate damaged cells [12, 13]. This is a delicate balance of risk versus reward the cell
is programmed with, to choose death rather than risk proliferating with improperly
repaired DNA that could potentially carry through development leaving opportunity for
mutations resulting in severe neural consequences, like tumorigenesis [14]. Genome
stability is critical for all neural development, but it is especially important for the largest
and arguably the most complex portion of the human brain, the cerebral cortex. This
multifaceted process of genome stability and DNA repair throughout neural development
is best summarized by (Figure 1-1).
Corticogenesis
The main phase of cortical neurogenesis last about 12 weeks, with most neurons
not fully maturing until almost 18 months after birth. Comparatively, the same
neurogenesis period of a mouse cortex is approximately only 8 days, with maturation
completing around 14 days postnatal [15]. Although the difference in neurodevelopment
timing between humans and mice is vast, we must consider the comparative size. The
human cortex is over 1000 times larger by area and number of neurons than that of the
mouse cortex [16]. Even so, the cerebral cortex of mice make for exceptional
experimental models because this region of the brain is highly conserved across
mammals including the basic principles of corticogenesis and overall anatomical
structure [8, 15]. Mouse cortical development starts at embryonic day 10 (E10) in the
ventricular zone (VZ) with neural stem and progenitor cells undergoing a very unique
process called interkinetic nuclear migration, where the cells nuclear positioning is
reflective of its particular cell cycle phase (Figure 1-2) [17-20]. This process consists of
progenitor cells, starting at the apical layer of the VZ in G1 phase of the cell cycle, then
migrating up to the subventricular zone (SVZ) into S-phase at which point the progenitor
is considered basal because of the location. The basal progenitor eventually migrates
back down to the apical surface where it goes through G2 and finally mitosis [18]. From
this point the regenerative stem cell progenitor starts the process over again while the
daughter cell migrates away from the VZ [17, 21]. The daughter cells use radial glial
(RG) cells as scaffolding to migrate towards the SVZ to begin differentiating into
neurons, astrocytes or oligodendrocytes which makes up a vast amount of the cortical cell
layering process [22]. Glial cells and neurons will continue migrating and eventually
mature to build the intermediate zone (IZ), then the cortical plate (CP) and lastly the
marginal zone (MZ) in an innermost first and outermost last fashion [19, 21]. In the
mouse, cortical development begins at E10 with the rapidly proliferating apical
progenitors undergoing symmetric divisions until about E12 [19, 23]. Uniquely, these
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Figure 1-1. DNA damage repair in early neural development.
Neural development transpires through generalized cellular stages: proliferation,
differentiation and migration. This begins at the stem and progenitor cell step that divide
and start to form the ventricular zone (VZ) and some of the subventricular zone (SVZ).
From this point cells undergo differentiation, migration and lastly maturation to give rise
to the majority of cells in the adult brain including neurons and glia, consisting of
astrocytes and oligodendrocytes. Cells are susceptible to various forms of DNA damage
at the different stages of development. During proliferation, replication stress can induce
DNA strand breaks that require DNA double strand break repair (DSBR) through
homologous recombination (HR) or non-homologous end-joining (NHEJ). In
differentiating cells DNA repair options are more restricted as HR is unavailable after
cells exit the cell cycle. At this stage, NHEJ becomes the main pathway for DSBR, while
other forms of DNA damage utilize nucleotide excision repair (NER) or single strand
break repair (SSBR). Neural cells can be easily replaced during early development;
therefore, DNA damage-induced apoptosis is a frequent result. Mature neurons and glia
rely on NHEJ, SSBR, NER and various other forms of DNA repair to address DNA
damage from strand breaks and reactive oxygen species from oxidative metabolism.
DNA this unable to be repaired at these last stages can disrupt transcription leading to
cell death.
Modified with permission from Springer Nature. McKinnon, P.J., DNA repair deficiency
and neurological disease. Nat Rev Neurosci, 2009. 10(2): p. 100-12.
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Figure 1-2. Mouse cortical development schematic.
Stem and progenitors cells initiate corticogenesis around E10 in which they undergo a
process of interkinetic nuclear migration where the nuclei of these cells or radial glia
(RG) cells occupy different positions along the apical-basal SVZ axis depending on the
phase of the cell cycle. As cells progress through neural lineage they use RGs as
scaffolding to migrate away from the apical surface and become differentiated/mature
cortical neurons. Radial migration can be broken into four phases by unique cell types.
Newborn neurons, like apical radial glia (aRG) committed to neurogenic lineage (aRG-N)
leave the proliferative areas (aRG-P) (I) and reach the SVZ/IZ, where they attain a
multipolar morphology (II). After pausing in the SVZ/IZ at the basal layer (bRG), cells
migrate toward the CP, using kinetic energy (III). At the end of their migration, cortical
neurons switch to translocation of the soma (IV). During the transition to differentiation
and maturation the cells exit the cell cycle.
Modified with open access permission. Azzarelli, R., F. Guillemot, and E. Pacary,
Function and regulation of Rnd proteins in cortical projection neuron migration. Front
Neurosci, 2015. 9: p. 19.
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cells have a longer S-phase of about 8 hours during this critical developmental time
period to allow for enhance genome surveillance [24]. As the progenitor cells undergo
differentiation and transition to neurogenic divisions around E13, S-phase shortens to
about 2-3 hours, while the G1 phase lengthens [21, 25]. Mouse corticogenesis is not
considered complete until almost post-natal day 14, although a majority of the cortical
layers are well established by E18. Decades of research on this complex developmental
process has generated many unique markers for immunohistochemistry (IHC) that can be
utilized to precisely identify and study the effects of specific gene mutations on the cortex
[26-29]. Of particular importance to this dissertation, mutations in DSBR genes can be
investigated for the effects of their loss on cortical layers like cell cycle progression,
neuronal maturation and cell death throughout early brain development [14].
Double strand break repair pathways
HR and NHEJ involve multiple repair genes and associated proteins (Table 1-1
and Figure 1-3). Repair enzymes associated with the HR pathway are: ATM (Ataxia
Telangiectasia, Mutated), ATR (ATM and Rad3-related), MRN complex (Mre11, Rad50,
NBS1), RPA (replication protein A), BRCA1 or 2 (breast cancer type 1 or 2 susceptibility
proteins) and a group of Rad51-related proteins [30-33]. HR repairs DNA by utilizing an
undamaged homologous DNA strand template, sister chromatid, to replicate and replace
a parallel damaged one [33, 34]. This process starts with the MRN complex sensing a
DSB and signaling for activation of ATM. ATM then autophosphorylates to form active
monomers, which are recruited to the DSB to signal for cell cycle arrest through Chk1 or
Chk2 to allow for DNA repair to proceed [12, 35, 36]. MRN then works to resect a DSB
creating a 3’ ssDNA tail, which is immediately coated with RPA. RPA is then replaced
by Rad51 complex proteins, along with BRCA1/2, to assist with invasion of the sister
chromatid. The proteins search for a homologous sequence on the ssDNA and once
found, DNA polymerase will come in to extend the 3’ end to form a Holliday Junction
which is ligates the breaks together using DNA ligase I (LIG1) [33, 34]. These junctions
are eventually removed by Rad54 after repair is complete. Similar to ATM, ATR can also
activate MRN and the HR pathway, in situations of replication stress and stalled
replication forks leading to DSBs [11, 37]. ATR is either initiated by RAD9–RAD1–
HUS1 (9-1-1) complex which recognizes RPA-bound ssDNA generated by stalled
replication forks, or by MRN resection of DSBs, where it forms a complex with coactivator ATR-interacting protein (ATRIP). This complex then localizes to an additional
activator, topoisomerase II binding protein 1 (TopBP1) which leads to phosphorylation of
downstream substrates like Chk1 and p53 to modulate cell cycle progression. HR is
considered to be error-free and is especially important for replicating cells, like cortical
progenitors, during the late S and early G2 phase transition. This is because of the limited
access to sister chromatid, or a complementary DNA strand, during this time period of
the cell cycle [38, 39].
In contrast, NHEJ is more error-prone because it does not use a homologous
template. Instead it functions by directly modifying the two DNA end breaks so that they
are compatible enough and then bluntly ligates them together, as a result some
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Figure 1-3. DNA double strand break repair pathways.
Double strand breaks can be repaired through two different pathways which is dependent
on a cells proliferative state. (A) Homologous recombination (HR) is primarily available
in the highly proliferative or replicating cells. Replication Protein A (RPA) covers the
resected ends of the single stranded DNA and recruits Rad51 complex proteins along
with other factors, including BRCA2 and XRCC2. These proteins work together to repair
the DNA via a process where the template DNA from a sister-chromatid is incorporated
into the damaged strand and acts as an error-free template. Lastly, the breaks are ligated
together by DNA ligase I (LIG1). (B) Non-homologous end-joining (NHEJ) can repair
DSBs in both proliferating and non-proliferating cells when needed. Heterodimeric
KU70/KU80 bind broken DNA ends and recruit DNA-PK (DNA-dependent kinase
catalytic subunit). Together, with XLF, XRCC4 and DNA ligase IV (LIG4), this complex
works to reseal the broken DNA ends after processing from several nucleases. NHEJ is
often considered an error-prone repair mechanism because some nucleotides may be lost
in this process.
Modified with permission from Springer Nature. McKinnon, P.J., DNA repair deficiency
and neurological disease. Nat Rev Neurosci, 2009. 10(2): p. 100-12.
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nucleotides may be lost in this process [40]. Critical repair enzymes for the NHEJ
mechanism, include Ku70/80 heterodimers, DNA-PKcs (DNA-dependent protein kinase
catalytic subunit), XRCC4 (X-ray repair cross complementing 4) and DNA ligase IV
(LIG4) [33, 41, 42]. NHEJ is initiated by Ku70/80 binding to DSBs, which recruits DNAPKcs. Once the Ku heterodimer and DNA-PKcs join they form an active serine/threonine
protein kinase complex called DNA-PK [43]. The DNA-PK complex positions the DSB
ends to be merged together and recruits the exonuclease Artemis. Artemis resects DNA
ends and lastly allows for XRCC4, XLF, and LIG4 to come in and complete the ligation
process [44]. Additionally, there are alternative NHEJ pathways that use MRN and
similar components, XRCC1 and LIG1/3, but these are less-efficient backups [45, 46].
Although NHEJ may be an imperfect process it still repairs the DSBs and therefore the
errors that may occur likely result in little consequence in non-proliferating cells [6].
NHEJ also remains an essential pathway for DSBR throughout the cell cycle, especially
during G1, early S and late G2/M stages, when HR is not available [47].
While HR is the preferred and primary route of DNA repair in highly proliferative
cortical progenitor cells because of its high efficiency, NHEJ acts as a backup if needed
[48]. However, the role of these repair pathways effectively switch as cells differentiate
and mature. NHEJ becomes the main form of DSBR in postmitotic mature neurons later
in brain development because HR is essentially nonfunctional once the cells exit cell
cycle [6]. Deficiencies in either DSBR pathway can result in accumulation of DNA
damage [11, 49]. If DSBs within cortical progenitors cannot be repaired by HR or NHEJ,
then they will usually undergo apoptosis to eliminate the damaged cells and avoid the
chance of acquiring mutations. Apoptosis is most commonly activated by ATM through
Chk2/p53-signaling pathways [50]. The DNA damage signaling process has many unique
steps pertaining to the specific repair pathway, however some of the initial events are
common among both of them. One of the first steps is the phosphorylation event on the
histone H2A variant X at Serine 139, (γH2AX) [51, 52]. γH2AX is a chromatin
modification that is primarily activated at DSBs via ATM or DNA-PK, and subsequently
recruits other DDR machinery to begin the repair process [53]. Identification and
visualization of γH2AX foci, synonymous with DSBs, has been standardized through
many methods including IHC, western blotting, chromatin immunoprecipitation and flow
cytometry [54, 55].
Double strand break repair deficient mouse models
Mice are useful models to study DNA repair mutations, especially in the context
of the nervous system. This is because inactivation of DNA repair factors display
profound tissue specific effects [14, 56]. Inhibition of either HR or NHEJ in mice has
been shown to disrupt normal nervous system development, leading to neurodegenerative
diseases, microcephaly, brain tumors and embryonic lethality [49, 57, 58]. DSBR genes
are important for maintaining genome stability in numerous early developmental
processes, thus germline inactivation of many of these genes result in embryonic lethality
or perinatal death [59]. However, less detrimental effects are observed when gene
deletion is restricted to specific organs, such as Nestin-cre which is active in neural
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progenitors. Nestin-cre is a cre recombinase that drives gene deletion throughout the
entire mouse brain (Nestin-positive cells), commencing around E10-E11 [60, 61]. For
example, when ATR, a PI3K-like protein kinase that is involved in DDR, is selectively
inhibited with Nestin-cre it produces a substantially reduced cerebellum size, which is
relatively negligible considering germline deletion is embryonically lethal [11, 62, 63]. In
the context of HR, our lab has shown the loss of Brca2 alone results in overall brain size
reduction with Nestin-cre, due to DNA damage induced apoptosis [58]. However, with
additional germline inhibition of p53 these mice develop medulloblastomas with greater
than 80% incidence. Mutations of BRCA2 are not only responsible for breast and ovarian
cancer, they are also found in some cases of Fanconi Anemia (FA), a rare autosomal
recessive cancer susceptibility syndrome [64, 65]. FA patients have an increased
sensitivity to DNA cross-linking agents and in cases with BRCA2 mutations they display
more severe phenotypes, including predisposition to medulloblastomas [66, 67].
Similarly, work from our lab has shown, conditional inactivation of Lig4 and/or Xrcc2
with null p53 again produces medulloblastomas at high frequencies (>90%) [49].
Mutations in LIG4 (LIG4 syndrome [68]) commonly cause neurodevelopmental defects
in humans, including microcephaly. Although p53 plays a somewhat indirect role in
DSBR, as a response effector, it should be noted that germline p53 mutations alone in
mice usually do not result in medulloblastoma formation, as the mice develop
lymphomas instead [49, 69-71]. Additionally, conditional inactivation of p53 alone with
Nestin-cre eventually result in limited medulloblastoma and glioma development
however at a much later latency and far less frequency than what is found in humans with
similar p53 mutations in neural tissue [49, 69]. In summary, the use of Nestin-cre to
induce whole brain inactivation of DSBR genes requires concurrent inactivation of the
p53 pathway and frequently results in medulloblastoma formation [72].
Similar end resulting phenotypes, like medulloblastomas, from the use of Nestincre have driven the utilization of highly tissue specific cre promoter lines to further
evaluate the effects of DSBR loss on different regions of the brain, like the cortex, which
can be targeted with Emx1-cre [59, 73]. Emx1-cre expresses earlier than Nestin-cre
(~E9.5 vs. ~E10.5, respectively) and occurs primarily in the dorsal telencephalon, which
develops into the neocortex [61, 73, 74]. Previous work from our lab has employed
Emx1-cre to inhibit DNA repair related genes like TopBP1, a protein linked to DNA
replication and activation of ATR [75]. Remarkably, inhibition of TopBP1 by Emx1-cre
resulted in a complete loss of cortical structures, while use of Nestin-cre produced a
much milder phenotype. In this case, the comparative utilization of Emx1- and Nestin-cre
revealed the essential role TopBP1 plays in preventing replication-associated DNA strand
breaks in early cortical progenitors. In that same study, Lig4 was also conditionally
inactivated by Emx1-cre, and although these mice suffered substantial DNA damage and
cell loss in the cortex, which resulted in reduced cortical size, they had no obvious health
issues and lived normal lifespans [75]. This was also the case for Brca1 inactivation by
Emx1-cre, although in this scenario only early-born progenitors experience apoptosis
while any progenitors after E16.5 were relatively unaffected [76]. This underlines the
necessity of exploring different spatiotemporal gene deletion methodologies for DSBR in
the context of the mouse brain, because dramatically different phenotypes can result from
targeting specific genes, cell populations and developmental time periods. The mouse
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brain is a good model to study not only DNA damage repair but more importantly to
study the mechanisms of human disease such as glioma development.
Gliomagenesis
Brain and nervous system tumors are the rarest forms of malignancies in adults,
accounting for less than 3% of the total U.S. cancer cases and deaths in 2019 [2, 77].
Unfortunately, these are the most common solid malignancies found in children (~26%)
and only second for overall pediatric cancers behind leukemia (~28%) [2, 77]. Adult and
pediatric brain tumors may have remarkable clinical differences but they both are still
extremely rare occurrences and the general etiology is unknown for most [78]. Advances
in genome sequencing have allowed us to analyze thousands of matched tumor and
normal samples in attempt to uncover common gene alterations among brain tumors [7982]. Many significant discoveries have come from these studies, including the
identification of unique gene mutations, including EGFR, PDGFRα and H3K27M, shared
among specific types of pediatric tumors, such as gliomas, which are distinguishable
from similar morphological adult gliomas (further elaborated in following sections) [8185]. However, overall pediatric tumors were found to carry few germline mutations and
tend to have less total mutations than adult malignancies, with variations dependent on
the particular type of cancer [86-89]. For instance, some pediatric high-grade gliomas
have very low mutational burden while others have a hypermutator phenotype [88, 90].
The genetic heterogeneity of brain tumors add to disease complexity, which drives our
need to better understand the developmental processes underlying pediatric
gliomagenesis to allow effective therapeutic treatment and improve patient outcomes.
Amongst the many forms of pediatric brain tumors, gliomas are the most
prevalent [77]. A glioma is any tumor arising from glial cells, such as astrocytes and
oligodendrocytes, which encompass the critical support network for cells in the nervous
system [91, 92]. Through the advanced sequencing techniques and histological analyses,
biopsies of gliomas can be categorized by the stage or grade and the cells from which the
tumor arises for more accurate characterization [77]. There are four classic stages of
gliomas ordered from least severe, low-grade (I and II), to most with high-grade (III and
IV). Low-grade gliomas (LGGs) are most frequently diagnosed in children and
accordingly have the best prognosis, while high-grade gliomas (HGGs) are predominate
in adults after middle age and have worse outcomes [77]. Pediatric HGGs (pHGGs),
which is a main focus of this dissertation, make up about 20% of the annual pediatric
glioma cases with astrocytomas, oligodendrogliomas and ependymomas encompassing
the majority [93]. HGGs in adults are primarily found in the supratentorial region of the
brain, mostly composed of the cortex, while in children these gliomas are usually
identified in the posterior fossa made up of the cerebellum, brainstem and diencephalon
[88, 94]. Although HGG locations may differ between human ages, the standard
treatment for both are usually surgical resection, radiation and chemotherapy
(temozolomide) which result in suboptimal survival results [95, 96]. Gliomas are
typically characterized by the cellular composition present at diagnosis, the question of
whether gliomas originally arise from that same cell type or are transformed from another
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type has been a highly contested research topic, which is commonly known as the “cell of
origin” [91, 97-99]. Many studies have used both genetic analysis of human samples and
novel glioma mouse models in attempt to answer this question to help better understand
the mechanisms of gliomagenesis [100-102]. Potential cells of origin for gliomas include
neural stem cells (NSCs), glial or astrocyte progenitor cells, oligodendrocyte progenitor
cells (OPCs) and differentiated astrocytes [91, 97]. To understand why these particular
neural cells would be sources of gliomagenesis, we must also have an appreciation of
how glial cells develop in the brain through gliogenesis.
Gliogenesis and the cell of origin
Corticogenesis and gliogenesis overlap in many ways and both are complex
processes involving diverse cell populations beginning with stem and progenitors and
eventually ending with mature neurons, astrocytes and oligodendrocytes. Identifying the
correlation of the developmental steps from the origination of these cells to when and
how they become tumor cells has been studied by many research groups often in mouse
models [91, 97, 103]. All glial cells ascend from regenerative NSCs through a process of
asymmetric divisions giving rise to intermediate progenitor cell populations, like OPCs.
This first round of progenitor production begins around E12 in the mouse cortex, with a
second round starting at E15 and the final round at birth [92, 104]. Neuronal and
astrocytic progenitors are usually short lived in early development with rapid
differentiation into mature neurons and astrocytes [104]. Uniquely, OPCs can not only
yield oligodendrocytes but they often remain as precursor cells in certain locations in the
adult brain. Similarly, some NSCs can persist into adulthood, taking up residence in the
SVZ and dentate gyrus [105]. With a presence in the adult brain and susceptibility to
transformation due to proliferation, NSCs have emerged as plausible cell of origin
candidates in multiple laboratories [100, 106, 107]. These studies showed that by using
direct retroviral delivery systems of known oncogenic mutations, including p53, Pten, Rb
and Nf1, in NSCs, gliomas can reproducibly developed in mouse models [100, 101, 107].
Astrogliogenesis begins at E16-18, with the majority of astrocytes being
generated in the first three weeks after birth, although some proliferating astrocytes can
be found up to 52 days of age [108, 109]. Because astrocytes are highly proliferative and
create large cell populations in the brain some groups are studying their possible role in
gliomagenesis. The properties of astrocytes make them easy to isolate and a stable cell
population to manipulate and implant into mouse models to successfully generate
gliomas. Studies that have shown such in vitro models have done so by isolating
astrocyte cultures from p53- or Ink4a/Arf-null mouse backgrounds and then
overexpressing common oncogenes, such as MYC, RAS, AKT, PDGFR, and EGFR and
implanting back into mice which result in gliomas [102, 110-116]. Further evidence
supporting astrocytes as cells of origin came from a Cre-inducible model targeting glial
fibrillary acidic protein (GFAP) positive cells in adult mice [117]. One study using
GFAP-cre produced spontaneous astrocytomas that were reflective in location of
originating from mature astrocyte populations, by mutating Pten and p53 with or without
Rb deletion [101]. However, some gliomas in this model were identified in highly
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proliferative niches which is more indicative of NSCs, which also express GFAP,
suggesting that either NSCs or astrocytes could be transformed into malignant gliomas.
More recently, OPCs have become a strong contender for a cell of origin in
gliomagenesis. Similar to astrocytes, a majority of oligodendrocytes come from the
progenitors produced in the last round of gliogenesis after birth [104]. OPCs can also be
found after development in the adult brain in slowly proliferating populations that are
actually larger in total numbers than NSCs [118, 119]. OPC expression has been
identified in many human glioma samples which commonly match with the molecular
signature of proneural subtype gliomas [120-122]. Many mouse models have shown
OPCs capability to generate gliomas with the introduction of common human glioma
mutations, including p53, PTEN, Nf1 and Ras [102, 123, 124]. Some of the best evidence
supporting OPCs being a cell of origin came from a new model system developed to
accurately trace cell lineages through gliomagenesis with the introduction of mutations,
p53 and Nf1 in NSCs and OPCs [91, 102]. By fluorescently tracking the mutations
introduced to either cell type they found that OPC gliomas were indistinguishable from
NSC induced gliomas. These studies together suggest that the susceptibility to glioma
formation decreases with neural lineage restriction, indicating that NSCs, progenitors and
specifically OPCs may be the more likely initiating cells [98]. Although the cells of
origin in glioma is still not clear, understanding this will guide the development of more
effective cancer treatments.
Genetics of high-grade gliomas
Adult and pediatric gliomas are two very distinct diseases; however, they do share
some overlapping characteristics, including some similar genetic mutations. One of the
first mutations studied in pHGG were epidermal growth factor receptor (EGFR)
alterations because these were commonly found in adult HGGs (aHGGS) [125].
Although, EGFR variant III (EGFRvIII) mutations were identified at a much lower
frequency in pHGGs this indicated the first signs of genetic similarities between pHGG
and aHGGs [126, 127]. Other growth factor receptors like platelet-derived growth factor
receptor alpha (PDGFRα) and fibroblast growth factor receptors 1/2/3 (FGFR1/2/3) are
often amplified and/or mutated in both pHGG and aHGGs [111, 128-131]. In addition to
these, mutations in common tumor suppressor genes are also found in HGGs, like
phosphatase and tensin homolog (PTEN) and P53 [83]. Similar to EGFR, mutations of
PTEN are less commonly found in pHGGs with 5-15% occurrence, compared to 25-40%
in aHGGs [126]. Adult and pediatric HGGs contain diverse genomic landscapes and
further observations within different types of pHGGs discovered clear differences
between their own genetic etiologies.
Specific types of gliomas are often identified by their originating location. One
example is diffuse intrinsic pontine gliomas (DIPGs), which are HGGs derived from the
brainstem and pons that infiltrate or diffuse to surrounding normal brain tissue. DIPGs
harbor additional specific mutations at slightly higher rates than other types of pHGGs,
such as PDGFRα and p53. For instance, p53 mutations occur in about 50% of DIPGs,
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while only in 20-35% of pediatric non-brainstem HGGs [80, 94, 132]. Besides mutations
in p53, other DNA repair related gene mutations are sometimes found in pHGGs, such as
ATM, ATR, BRCA2, RAD50 and several Fancomi anemia genes [80]. Other more
frequent alterations in DIPGs include amplification of cyclin D genes, CCND1/2/3 (about
30%) and mutations in CDKN2A which encodes for the tumor suppressors p19/ARF and
p16/INK4A [128, 133, 134]. Notably, a high incidence of mutations in histone H3 are
also associated with DIPGs (see next section). DIPGs are particularly rare in both adults
and children. However, brainstem HGGs occur much more frequently in children with
approximately half of all pHGGs being DIPGs [77, 96]. Additionally, in younger patients
the probability of fatality increases dramatically, with median survival rates less than one
year after diagnosis [80, 93, 96]. The poor prognosis and low survival rates are largely
due to the unique location and infiltrative nature of the tumor, making surgical resection
almost impossible and radiation is only marginally effective in these children [135, 136].
The unique and challenging characteristics of pHGGs and DIPG highlight the need to
better understand the underlying genetic mechanisms of gliomagenesis to develop more
effective targeted treatment strategies.
Oncohistone Mutations
Whole-genome sequencing has identified unique histone mutations as a common
occurrence among subsets of HGGs. DIPGs and other pHGGs were found to frequently
harbor somatic mutations in the N-terminal tail of histone H3 [81, 82]. Two of these
specific missense mutations were a lysine to methionine substitution (H3K27M) and a
glycine to arginine or valine (H3G34R/V). H3K27M mutations are predominantly found
in midline or cerebellum originating tumors in younger patients, while other histone
mutations such as H3G34R were identified in gliomas arising primarily in the cerebral
hemispheres in slightly older patients [88]. H3K27M patients tend to have a worse
prognosis and for this reason the presence of the H3K27M mutation has recently been
incorporated into the World Health Organization classification as a diagnostic marker for
HGGs [137]. Histone mutations have also been identified in adult cancers like leukemia
and other HGGs, albeit at a much lower frequency (less than 1%) compared to pHGGs
(~50%) [80, 138-140]. Recent large collaborative efforts have molecularly analyzed a
substantial amount of these rare H3K27M gliomas revealing the biological and genetic
heterogeneity of these tumors [79, 80, 82, 90, 120, 141]. Intriguingly, these studies
identified additional mutations of oncogenic pathways in the H3K27M tumors, including
receptor tyrosine kinase signaling pathways (BRAF, FGFR1, ACVR1, PIK3R1 and
PIK3CA) and pathways involving DNA damage repair mechanisms (TP53, ATM,
PPM1D, ATRX, BLM and TOP3A). Notably, TOP3A, encoding for DNA topoisomerase
III alpha, forms a complex with the bloom syndrome gene (BLM) which together
facilitate the processing of HR intermediates [142, 143]. Many of these genomic
aberrations represent promising therapeutic targets [80, 144]. Taken together, the unique
clinical characteristics of the pHGGs that frequently result from these histone driven
mutations and the oncogenic features they exhibit, has given them the term
“oncohistones”. These defining oncohistone events suggest that H3K27M mutations may
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arise at different developmental time periods as well as from independent positions and
cellular precursors, than tumors driven by other histone mutations, like H3G34R.
Distinctive features further support the concept that histone mutations are a
dominant gain of function event in tumorigenesis. For example, all oncohistone
mutations found in pHGGs are heterozygous. Additionally, although 15 genes code for
histone H3, only 1 is mutated in any given glioma sample [81, 82]. There are three main
variants of histone H3; H3.1 and H3.2 are only synthesized in chromatin during DNA
replication or S phase and H3.3 is replication independent, processed throughout the cell
cycle and is therefore found in the regions of both active gene transcription and
heterochromatin [145, 146]. Although, H3K27M only requires a single mutant allele this
mutation results in a drastic loss of the repressive-associated mark, H3K27me3,
throughout affected cell populations [147, 148]. This is due to the mechanism of
methylation in these cells. The histone modification H3K27me3 is mechanistically
deposited on chromatin by the polycomb repressive complex 2 (PRC2) to repress gene
expression [149, 150]. It has recently been shown that large amounts of the H3K27M
mutation are required compared to the relative quantity of PRC2 present in any given cell
to yield the loss of H3K27me3 [151]. This suggests that specific neural cell populations
may be more susceptible to the effects of H3K27M corresponding to the levels of PRC2.
Further support of this explanation is the evidence that repressing PRC2 can prevent
differentiation in embryonic stem cells resulting in a stem-like state [152]. One
hypothesis is that loss of H3K27me3 may reset potential cell of origin populations like
neural precursor cells or OPCs back to an earlier stem cell like state, leading to altered
cell identity [153].
H3K27M glioma mouse models
Recent studies using murine models have employed various strategies to mimic
the H3K27M oncohistone effect to induce HGGs, including in utero electroporation and
avian retroviral vector systems [154-158]. Although these models successfully induce
gliomas and some HGGs they have limitations. First, they all require additional
oncogenic drivers because H3K27M expression alone does not generate tumors. Another
caveat is the source of gene activation/inactivation in these mouse models, including
varying levels of exogenous H3K27M overexpression using viral transduction.
Furthermore, the procedures are complex with in utero electroporation, in vivo retroviral
transductions and/or pre- and post-natal embryonic injections being required. Therefore,
these models do not always recapitulate the spontaneous and endogenous formation
properties of pediatric gliomas. A more efficient model for gliomagenesis research was
recently developed containing a conditional knock-in allele of the H3f3a H3K27M
mutation [159, 160]. This model allows conditional activation with the inducible histone
mutation from the endogenous locus which is controlled by a Cre recombinase-activated
promotor. Using Nestin-creER for gene activation at postnatal days 0 and 1, which targets
a later subset of neural stem and progenitor cells, mice effectively develop DIPGs with
high penetrance in combination with PDGFR activation and p53 inhibition, which
closely models mutations found in pHGGs. pHGGs like DIPG are almost always a
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combination of mutations involving but not limited to growth factor receptors, epigenetic
modifications and tumor suppressors [90, 139, 161]. Since p53 mutations occur in about
half of pHGGs, with most being found in cerebral hemispheres, concomitant inactivation
of the p53 pathway is pertinent in modeling these types of brain tumors in mice [49, 80,
94]. The location and degree of glioma severity in this model displays one of the most
highly replicative examples of pHGG in a murine setting. One consideration in working
with this model is that spontaneous H3K27M activation using Nestin-cre produced
neonatal lethality, again highlighting the complications of creating a true endogenous
HGG murine model; it requires restriction of spatial and temporal expression. Although it
is unknown why the combination of H3K27M and Nestin-cre leads to neonatal death, it is
clear that the targeted neural cell population and timing of gene activation plays an
important role in this. More recently the inverse relationship of H3K27M mutation,
where H3K27M is depleted, has been studied using mouse xenografts to examine the
effect on tumor growth compared to an isogenic HGG setting [150, 162, 163]. The loss of
H3K27M by nonsilencing shRNA in patient-derived xenograft models decreased tumor
formation and increased survival [162], further supporting the detrimental significance of
this oncohistone in gliomagenesis.
H3K27M gene expression patterns
Sequencing and expression data from many studies suggest H3K27M is
associated with perturbing neural lineage differentiation, including comparable cellular
subsets to other HGGs such as OPCs, cycling cells and astrocyte- and oligodendrocytelike cells [120, 155, 160]. While the variants H3.1- and H3.3K27M both drive DIPG
formation, gene expression analysis of tumors carrying each suggest that H3.1 tumors are
more astroglial and mesenchymal in nature, whereas H3.3 are further oligodendrocytic
and proneural [164, 165]. The discovery of bivalent gene promoters brought about further
gene expression scrutiny to the H3K27M mutation because of its loss of the H3K27me3
mark [166]. A bivalent promoter is considered any nucleosome that has both H3K27me3
and H3K4me3, repressive- and activating-associated marks, respectively. The Baker lab
discovered that H3WT tumors had about 10% of the total gene promoters with both
bivalent marks in their mouse model [160]. Strikingly, more than 50% of promoters of
genes that were upregulated in H3K27M gliomas were considered bivalent in the H3WT
samples. This suggests that the loss of H3K27me3 on a poised bivalent gene promotor,
due to the H3K27M mutation, results in an overall upregulation of gene expression as
long as H3K4me3 is present for activation. Another activation-associated histone
modification, H3K27acetylation (H3K27ac), has been reported to have increased
expression in H3K27M tumors [149, 151, 163]. Specifically, the increase in H3K27ac at
enhancers and super-enhancers, large clusters of enhancers, in HGGs suggests this
mutation may be driving gene expression in putative cell of origin populations, like OPCs
[167, 168]. Although it has been shown that the H3K27M mutation undoubtedly
contributes to brain tumor development, many of the underlying mechanisms of its
function remain unclear.
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Research Objective
This dissertation investigates the effects of inhibiting DNA DSBR pathways via
loss of either BRCA2 (HR) or LIG4 (NHEJ) with associated p53 inactivation during the
earliest stages of cortical development in a physiological setting. The subsequent chapter
analyzes an innovative conditional knock-in H3K27M mouse (described above) to
examine the combinatorial effect of oncohistone mutations and DSBR-deficiency on
tumorigenesis in the cortex. Additionally, my studies have allowed us to further explore
the connections between H3K27M and genome stability. We hypothesized that the
oncohistone mutation affects the chromatin conformation state leading to increased DNA
damage susceptibility as part of the mechanism leading to gliomagenesis. Collectively,
these studies are the first to show an endogenous, spontaneous, cortical high-grade
glioma murine model involving H3K27M alteration. Further, our data highlight the
dynamic role DNA DSBR plays during early corticogenesis in preventing genomic
instability and gliomagenesis.
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CHAPTER 2.

EXPERIMENTAL METHODS
Animals

Generation and genotyping of the conditional H3f3aLSL-K27M-Tag/+, Brca2LoxP/LoxP,
Lig4
, p53LoxP/LoxP and Emx1-cre mouse lines have been previously described [12,
36, 49, 71, 159, 160, 169]. The generation of the H3f3aLSL-K27M-Tag/+ mouse has also been
thoroughly described [159]. Brca2-floxed mice (exon 11) [71] were previously obtained
from the MMHCC repository at the NIH. Lig4-floxed mice contain LoxP sites
surrounding the single Lig4 coding exon and was generated as described [49]. Emx1-cre
mice were obtained from the Jackson Laboratory (B6.129S2-Emx1tm1(cre)Krj/J, JAX
#005628). We used conditional Emx1-cre recombinase activation/deletion to restrict
effected brain region to the mouse cortex (to avoid medulloblastoma formation that occur
when Nestin-cre is used [49, 58]). Mice of either sex were used for experiments.
Heterozygous mice for Brca2, Lig4, p53 and/or any combination lacking Emx1-cre were
considered control subjects as full conditional gene inactivation was not present.
LoxP/LoxP

Animals were housed in an AAALAC–accredited facility with a 12-hour
day/night cycle. A maximum of five adult animals per cage were allowed. All animal
experiments were carried out in accordance with US National Institutes of Health
regulations and were approved by the St. Jude Children's Research Hospital animal care
and use committee (IACUC).
Histology
Mice were perfused transcardially with 4% PFA while embryos were drop-fixed
in 4% PFA, and tissues were cryoprotected in 25% PBS-buffered sucrose solution,
embedded in optimal cutting temperature (O.C.T) compound, and sectioned sagittally at
10μm using an HM525 NX cryostat (Thermo Scientific). Immunohistochemistry was
performed after antigen retrieval as described previously [75]. The following antibodies
were used: anti-active caspase-3 (1:500; BD Biosciences, #559565), anti-phosphoH2AX-Ser-139 (1:200; Cell Signaling Technology, #2577L), anti-phospho-H3-Ser-10
(1:500; Cell Signaling Technology, #9701L), PCNA (1:500; Santa Cruz, #SC-56), antiTuj1 (1:500; Covance Research Products, #MMS-435P), anti-Tbr2 (1:200; Abcam
#23345), H3K27me3 (1:200; Cell Signaling, #9733), PDGFRα (1:200; Cell Signaling,
#5241), Olig2 (1:500; Millipore, #AB9610), H3K27acetylation (1:750; Active Motif,
#39685), GFAP (1:500; Sigma, #G3893). Immunostaining of active caspase-3
H3K27me3 and H3K27acetylation was visualized with a VIP substrate kit (Vector
Laboratories, #SK-4600) and biotinylated secondary antibody and avidin-biotin complex
(Vectastain Elite kit; Vector Laboratories, #PK-6100). Sections were counterstained with
0.1% methyl green (Vector Laboratories), dehydrated, and mounted with DPX (Fluka).
For fluorescence, FITC- or Cy3-conjugated secondary antibody (Jackson
Immunologicals) were used and counterstained with DAPI (Vector Laboratories, #H-
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1200) or propidium iodide (Vector Laboratories, #H-1300). TUNEL staining was done
using the ApopTag system (Millipore Bioscience Research Reagents).
For BrdU incorporation assays, pregnant mice at E15.5 were injected (60μg per g
body weight), and 2h after injection, embryos were drop‐fixed in 4% PFA and processed
for cryosectioning and anti‐BrdU (1:200, Abcam, #ab6326‐250) immunostaining was
assessed. Apoptosis was measured by caspase-3 staining. Hematoxylin and eosin staining
was also performed using a standard protocol [170]. At least three independent tissue
samples from each genotype was used for all experiments and analyses.
Quantification of γH2AX foci, Tbr2 and BrdU positive cells were performed
using the NIH ImageJ processing program. Quantification of PCNA, GFAP and Olig2
positive tumor cells were performed using Biotek Gen5 data analysis software.
In-vivo Tumor Models
Cohorts of mice were aged and monitored for brain tumor symptoms. Symptoms
included but not limited to; slow, weak or intermittent breathing, decreased movement,
dull, slouched, tottering movements or lateral position, decreased weight change,
roughened fur, and decreased or no flight reaction. When moribund, mice were
euthanized. The brain was carefully dissected, a portion of tumor was snap frozen and the
remaining tissue was fixed with 10% formalin and kept at 4°C. Snap frozen tissue was
used for RNA-sequencing and formalin fixed tissue was used for histology. Since our
experimental mice harbor a mixed strain background and different cohorts may produce
slightly different results, some mice were euthanized due to other symptoms such as
enlarged clavicle masses and submandibular cervical lymph node enlargements.
Human DIPG Data
Gene expression data from human DIPGs are from a previously published dataset
[90]. These datasets were used as comparisons for mouse tumor expression data,
especially for chromosomal rearrangements, gene-fusions and gene amplification
comparison as described below. Informed consent for specimen analysis was obtained
under protocols approved by the St. Jude Children’s Research Hospital Institutional
Review Boards.
RNA-Sequencing
Total RNA was isolated from tissue with TRIzol (Invitrogen) and library
preparation using TruSeq Stranded Total RNA Kit (Illumina): Double stranded cDNA
fragments were ligated with Illumina paired end adaptors, followed by size selection
(~200bp) and libraries were analyzed by HiSeq 2000 sequencing systems (Illumina).
Unsupervised hierarchical clustering was used to generate the top 1,000 most variable
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genes, which were selected using a median absolute deviation score. Statistical analyses
and visualizations were performed using Partek Genomics Suite 6.6 and Stats MP/11.2
software. RNA-seq reads were aligned to UCSC mouse reference genome mm9 assembly
using STAR software [171]. GSEA for gene set, H3K27M human tumor sample
(GSE34824), was taken from Schwartzentruber et al. [82] and identified in the compiled
“Gene Perturbations from Geo Up” in Enrichr.
Differential gene expression analysis
FASTQ sequences are mapped to the University of California Santa Cruz mouse
reference genome (mm9) and the gene-level fragments per kilobase of transcript per
million (FPKM) values and counts per million (CPM) computed for genome-wide
analysis of differentially expressed genes via LIMMA in R 3.6.0. Read count for each
gene was obtained with HT-seq [172]. Gene set enrichment analyses were carried out
using GSEA with MSigDB [173]. Specifically, we used “-metric signal2noise -set_min 4
-permute gene_set”. GSEA FDR 25% cutoff was applied to examine enriched gene sets.
ssGSEA was carried out using a non-parametric and unsupervised method; Gene Set
Variation Analysis (GSVA) package in r [174]. False discovery rates (FDR) were set at
<0.05. Unpaired student t-tests were performed for significance analysis. LogFC cutoffs
were <0.75 and p-values were <0.05. Enrichr from Icahn School of Medicine at Mount
Sinai was used for evaluating differentially expressed gene targets associated with
pathways [175, 176]. The Gene Ontology Consortium was used in addition to Enrichr for
pathway analysis. Much of the bioinformatic analysis of sequence data was performed in
a collaborative effort between our laboratory including, Susanna Downing, along with
assistance from the departments of Computational Biology and Bioinformatics.
Gene-fusion analysis
Fusion gene events were identified and classified through the use of CICERO, a
local assembly-based algorithm that integrates RNA-seq read support with extensive
annotation for candidate ranking. This data analysis was performed by the Center for
Applied Bioinformatics Department and Computational Biology department at St. Jude
Children’s Research Hospital. Detailed methods for CICERO are as described [177]
Analysis of apparent bivalency
For bivalent gene promotor analysis using RNA-seq mouse tumor data we used
reference datasets from [160] and [106] for direct comparisons. Statistical analysis of
enrichment of upregulated bivalent targets in H3K27M gliomas, differential expression
analysis was previously described [160].
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Whole Exome Sequencing Analysis
Whole exome sequencing analysis was performed by the Center for Applied
Bioinformatics Department and Computational Biology department at St. Jude Children’s
Research Hospital. Detail methods for exome-capture, illumina sequencing, identification
of somatic mutations in mouse and mapping to human, and validation of somatic
mutations to non-tumor mice can be found in the manuscript [178].
Graphing and Statistical Analysis
All graphs with statistical analysis were doing using Graph Pad Prism and
software. All results were tested through an Ordinary one-way ANOVA and then
individual comparisons were done by Tukey’s multiple comparisons test. Survival plot
analysis used log-rank Mantel-Cox test and Gehan-Breslow-Wilcoxon test. Statistical pvalues were as follows: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
Fluorescence In Situ Hybridization
The Cytogenetic Shared Resource Laboratory at St. Jude performed FISH. Ten
formalin fixed embedded (FFPE) mouse brain tumor tissue specimens were submitted in
order to determine by FISH if there is amplification of the FGFR2, EFGR, Met, PDGFRα
genes in the tumors. Purified FGFR2 (RP23-158N2), EGFR (RP23-295E4), cMET
(RP23-73G15), PDGRFa (RP23-55P22) were labeled individually with a reddUTP
(AF594, Molecular Probes) and a chromosome 7 control probe (RP23-297D6/7A3) with
a green-dUTP (AF488, Molecular Probes) by nick translation. Paraffin slides were
deparaffinized with xylene. Pepsin was used for protease treatment. The labeled probes
were hybridized to all the samples in a solution containing 50% formamide, 10% dextran
sulfate, and 2X SCC. The cells were then stained with 4, 6-diamidino-2-phenylindole
(DAPI) and analyzed.
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CHAPTER 3. RESULTS: DOUBLE STRAND BREAK REPAIR
INACTIVATION LEADS TO HIGH-GRADE GLIOMAS
A clear understanding of the role of DSBR during cortical development is crucial
for piecing together the tissue-specific requirements for DNA repair throughout
neurogenesis. Previous mouse models studies from our lab and others have helped to
identify the importance of BRCA2 during HR and LIG4 in NHEJ during neural
development. Three key findings from DNA repair deficient mouse models underpin the
foundation and reasoning behind the genetic approach used in this chapter. First,
germline inactivation of either Brca2 or Lig4 is lethal at mid or early gestation [179-181],
although coincident inactivation of p53 rescues lethality but promotes lymphoma and
medulloblastoma formation [49, 58]. Second, conditional neuraxis-wide inactivation of
Brca2 or Lig4 via Nestin-cre, which expresses in neural progenitors throughout the brain
[60], resulted in pronounced microcephaly. This microcephaly is associated with defects
in neurogenesis embryonically and during postnatal cerebellar development [49, 58].
Lastly, Brca2Nestin-cre or Lig4Nestin-cre in conjunction with p53 inactivation restricted
tumorigenesis to early onset medulloblastoma, which occur in the cerebellum or
hindbrain [49, 58]. Together these models have helped provide the framework and
importance of BRCA2 (HR) and LIG4 (NHEJ) during nervous system development,
especially to the granule neuron progenitor cell population in the external germinal layer
of the developing cerebellum. However, much is still unknown about the roles these key
DSBR factors play in cortical development. Therefore, work presented in this chapter
further deciphers the basis for tissue-specific disruption of genomic stability and
tumorigenesis in the mammalian cortex.
Emx1-cre Deletion of DSBR, HR or NHEJ, Result in Cortical Cell Loss
To prevent medulloblastoma formation and to determine how DSBR influences
cortical development, Emx1-cre was used to target cortical progenitors. Emx1-cre
expression occurs from embryonic day 9.5 (E9.5) primarily in the cortical progenitor
cells of the dorsal telencephalon, which specifically develops into the cortex or forebrain.
Comparatively, Nestin-cre, which was previously used, expresses in neural progenitors
throughout the entire brain about a day later, between E10-E11 [60, 61, 73]. Conditional
inactivation of Brca2 (Brca2LoxP/LoxP; Emx1-cre hereafter called Brca2Emx1-cre; similar
nomenclature is used for additional mouse genotypes) was used to inhibit the HR
pathway and inactivation of Lig4 (Lig4Emx1-cre) disabled NHEJ. Histological analysis to
examine the cortex in 9-month-old mice revealed microcephaly in both DSBR-deficient
mice (Figure 3-1A, B). Brca2Emx1-cre mice cortices were approximately 40% smaller
compared to controls, whereas Lig4Emx1-cre cortices were about 85% smaller compared to
control and ~25% smaller than Brca2Emx1-cre. This would suggest that both DSBR
pathways are crucial for normal cortical development, with LIG4 (NHEJ) even more so
than BRCA2 (HR). Because we predict that cellular loss is occurring during
corticogenesis, we next looked at the rate of apoptosis during embryogenesis at E15.5
using activated Caspase-3, a surrogate marker for apoptosis, and TUNEL (data not
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Figure 3-1. Emx1-cre inactivation of Brca2 or Lig4 result in cortical
microcephaly.
(A) Mouse brains display reduced cortex size at 9 months of age in DSBR mutants. (B)
H&E staining of sagittal sections shows the difference in adult cortex size in DSBRdeficient mice compared to p53Emx1-cre control. Brca2Emx1-cre 40% cortical reduction and
Lig4Emx1-cre 85% reduction, highlighted by dotted line. Scale bar, 1mm.
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shown). Caspase-3 immunohistochemistry (IHC) staining revealed that loss of the
respective repair factors impacted different cell populations and Lig4 inactivation
resulted in extensive cell death compared to Brca2 mutant tissue (Figure 3-2A).
Brca2Emx1-cre mutants contained marginal levels of apoptosis in deep layers of the cortex
compared to Lig4Emx1-cre where a majority of the cell death was localized in the upper
layers aligning with non-proliferative progenitors. The marked increase and location of
apoptotic cells in the developing cortex of the DSBR-deficient mutants is consistent with
increased levels of DNA damage as evidenced via increased H2AX expression (Figure
3-2A, B). H2AX-foci are strong indicators of DSBs, while pan-nuclear expression is
indicative of cellular death [51, 182]. Both foci and nuclear H2AX expression were
identified at E15.5 in lower and deep cortical layers of Lig4Emx1-cre embryos, although
predominantly in the deep layers for Brca2Emx1-cre. Overall, there was significantly more
DNA damage found throughout the cortex in Lig4Emx1-cre mice than Brca2Emx1-cre (Figure
3-2B). E15.5 time period was initially selected as a point of interest because the second
round of progenitor production begins and therefore is a highly proliferative stage of
cortical development, as shown with PCNA, a proliferating cell marker. However,
because the first round of cortical progenitors are produced at E12.5 we additionally
investigated this time point. Similar to the results found at E15.5, Lig4Emx1-cre embryos
had significantly more H2AX expression throughout the neocortex compared to
Brca2Emx1-cre at E12.5 (Figure 3-2C, D). Even three days earlier in embryogenesis it still
appeared that Brca2Emx1-cre had more damage in the lower cortical layers. We also
observed significant amount of caspase-3 expression throughout the cortices of both
Brca2Emx1-cre (shown) and Lig4Emx1-cre (data not shown). This data take together implies
that while both DSBR pathways are critical in providing genome stability to the
developing cortex they do so in a spatially preferential manner. BRCA2 and HR prevent
DNA damage and cell death in the lower cortical cell layers while LIG4 and NHEJ
provide a similar preventative mechanism throughout the entire cortex, however to a
greater extent in the upper cell layers.
DSBR-Deficiency and p53 Inhibition in a Mouse Neocortex Results in Gliomagenesis
Despite perturbed cortical development and increased DNA damage, the overall
observable phenotype and survival of the DNA repair mutants was not obviously
different to controls. Because we observed high levels of apoptosis in both Brca2- and
Lig4-deficient mice neocortices we were interested in what the consequence would be to
additionally inhibit p53-mediated apoptosis by crossing with a p53-conditional knock-out
mouse. Furthermore, knowing that both (Brca2;p53)Nestin-cre and (Lig4;p53)Nestin-cre mice
generate medulloblastomas from previous models our lab created [49, 58], we
hypothesized that Emx1-cre would have a similar tumorigenic effect on the mouse cortex.
We discovered, that coincident p53 loss with Brca2Emx1-cre or Lig4Emx1-cre resulted in highgrade gliomas starting at 6 months of age (Figure 3-3A). Notably, inhibition of either
repair pathway resulted in similar overall survival and tumor latency of about 10 months
(Figure 3-3A). Interestingly, tumor incidence was about 35% (15/44) in p53Emx1-cre mice,
although this ultimately was after almost 21 months for these controls. Tumor incidence
increased significantly to 44% (43/97) and 42% (45/108) in (Brca2;p53)Emx1-cre and
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Figure 3-2. Emx1-cre inactivation of Brca2 or Lig4 result in DNA damage and
cortical cell loss.
(A) Inactivation of Brca2 or Lig4 using Emx1-cre results in cellular apoptosis in distinct
cortical layers at E15.5 marked by active Caspase-3 staining. High levels of DNA
damage marked by γH2AX staining correlate with cellular loss. White hash mark
indicates upper and deep cortical layers. Close ups; white arrow indicates γH2AX-foci
(DSBs), red arrow indicates pan-nuclear γH2AX-signaling for cell death. PCNA is
representative of high proliferation at this state and side box indicates cortical layers. (B)
Quantification of E15.5 γH2AX expression (total foci and pan-nuclear) for upper and
deep layers and total neocortex combined. ****p<0.0001, n.s.= not significant. N ≥ 3 for
all embryo analysis. (C) Quantification of E12.5 γH2AX expression (total foci and pannuclear) for upper and deep layers and total neocortex combined. ****p<0.0001,
**p=0.0011. (D) DNA damage starts to accumulate at higher amounts during early
embryogenesis at E12.5 in Lig4Emx1-cre mice more than Brca2Emx1-cre. Representative
image of apoptosis is shown in Brca2Emx1-cre. All graphs represent mean values of
replicates. Error bars indicate SEM. Abbreviations: VZ: ventricular zone, SVZ:
subventricular zone, IZ: intermediate zone, CP: cortical plate, MZ: marginal zone.
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Figure 3-3. DSBR-deficiency and p53 inactivation in a mouse neocortex results in
gliomagenesis.
(A) Kaplan-Meier survival analysis in mice with induced mutant p53Emx1-cre (n = 15/44),
(Brca2;p53)Emx1-cre (n = 43/97), or (Lig4;p53)Emx1-cre (n = 45/108); Tumor incidence: (n =
# mice died of glioma / # total mice), ****p < 0.0001. n.s., not significant; p = 0.8869.
(B) Representative images of gliomas (top panels). Sagittal sections stained for H&E.
IHC of PCNA, Olig2 and GFAP of representative HGGs display differences in glial cell
populations. White dashed lines outline primary tumor(s). PCNA indicates tumor cell
proliferation and diffusion; numbers (4, 4 & 5) denote diffusion score in panel C. Scale
bar, 1mm for whole brain sections; 200μm for higher-magnification images. (C) Glioma
diffusion scores based on H&E and PCNA expression. Least diffuse (1) to highest (5).
Percentage of tumors analyzed with determined diffusion score. Representative tumors
for scores shown in panel B. p53Emx1-cre (n = 4), (Brca2;p53)Emx1-cre (n = 16), or
(Lig4;p53)Emx1-cre (n = 9) (D) Mouse characteristic glioma histopathology of pHGG
classifications with H&E. HGGs vary in classification of cell type involved in tumor
formation. (Analysis done by Dr. David Ellison). Scale bars: 100μm (Lowermagnification images), 50μm (Higher-magnification images).
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(Lig4;p53)Emx1-cre, respectively. Both DSBR-deficient gliomas display similar focal tumor
patterns throughout the cortices and olfactory bulbs with moderately low levels of
diffusion as seen in H&E and PCNA expression, which is commonly used to detect
tumor cells as they usually undergo high rates of proliferation (Figure 3-3B). These
markers were used to apply an unbiased diffusion score (1-5) based on localization of
primary tumor and overall dispersal of cancerous cells in representative samples of
mouse gliomas, as shown in (Figure 3-3B, C). Both DSBR mutant tumors exhibited
increased nuclear Olig2 expression (oligodendrocytic marker) and variable expression of
GFAP (marker for astrocytes and ependymal differentiated cells) compared to p53Emx1-cre
mouse tumors (Figure 3-3B). Similar pathology is often identified in pHGGs, in addition
to moderate nuclear pleomorphism (H&E), increased mitotic activity (PCNA) and broad
infiltration, all of which we identified [92, 137]. A subset of mouse gliomas were
assessed and classified by Dr. David Ellison, a clinical neuropathologist. The resultant
mouse gliomas were mostly heterogeneous, displaying classical features of several
different subtypes of HGGs, including astrocytomas, oligodendrogliomas, embryonal and
mixed glial gliomas (Figure 3-2C). To note, p53Emx1-cre mice eventually succumbed to
HGGs, albeit much later in age and at far lower frequencies (Figure 3-2A, B). Although,
this was not a surprise as p53 is not only a key protein in the apoptotic pathway but is
also one of the most frequently mutated tumor suppressors in all types of cancer,
including brain tumors [82, 88, 90, 183]. These data indicate disruption of genome
integrity by inhibition of Brca2 (HR) or Lig4 (NHEJ) coupled with p53 inactivation in
cortical progenitors strongly predisposes mice to HGGs.
Distinct Gene Expression Profiles Characterize HGG Arising from Disabled DSBR
HGGs typically display heterogeneity within subgroup classifications defined by
gene expression signatures including proneural, classical or proliferative and
mesenchymal [121, 125, 160, 184]. To explain potential mechanisms resulting in
heterogeneous glioma formation and diffusion from Brca2- or Lig4-deficiency in the
mouse cortex, we collected tumor tissue from (Brca2;p53)Emx1-cre, (Lig4;p53)Emx1-cre and
p53Emx1-cre mutants and performed transcriptome analysis through RNA-sequencing
(RNA-seq). Unsupervised clustering of HGGs revealed unique grouping of the most
differentially expressed genes between (Brca2;p53)Emx1-cre and (Lig4;p53)Emx1-cre gliomas,
reflective of partial tumor heterogeneity (Figure 3-4A). We identified 243 uniquely
upregulated genes in (Brca2;p53)Emx1-cre samples and 32 in (Lig4;p53)Emx1-cre using
standardized expression cutoffs. Initial glance at the 32 genes upregulated in
(Lig4;p53)Emx1-cre tumors we found three were Sox genes (Sox3, 10, 13), all involved in
embryonic development, cell fate determination and neural precursor differentiation . In
addition to Sox10, Insulin like growth factor 2 (IGF-2), was upregulated and interestingly
both of these genes are identified as enhancers of PDGFRα/β in pediatric gliomas,
specifically oligodendrogliomas (Sox10) [185-188]. Lastly, the proto-oncogene B-cell
CLL/lymphoma 3 (BCL3) was upregulated in (Lig4;p53)Emx1-cre tumors, which recently
has been associated with resistance to chemotherapy in gliomas [189]. Gene-set
enrichment analysis (GSEA) was performed using Enrichr, which is used for evaluating
differentially expressed gene targets associated with pathways. Through Enrichr, we
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Figure 3-4. Gene expression profiles characterize HGGs arising from disabled
DSBR.
(A) Unsupervised clustering of (Brca2;p53)Emx1-cre (n = 16) and (Lig4;p53)Emx1-cre (n =
10) HGGs reveal unique groupings of most differentially expressed genes reflective of
partial tumor heterogeneity. 243 genes upregulated in (Brca2;p53)Emx1-cre and 181 genes
downregulated ((Up in (Lig4;p53)Emx1-cre)). LogFC > 0.5, p-value > 0.05 and Avg.
Expression > 1.0. (B) Enrichr analysis indicates significantly enhanced associated
pathways in (Brca2;p53)Emx1-cre or (Lig4;p53)Emx1-cre tumor samples when compared to
each other. (C) Ccnd3 and Map3k1 display higher amplification in (Lig4;p53)Emx1-cre.
(Fragments Per Kilobase of transcript per Million mapped reads). (D) Enrichr pathway
analysis of DSBR-deficient gliomas juxtaposed to control p53Emx1-cre (n = 6) identifies
upregulation of genes involved in DNA damage response and RNA processes, in
(Brca2;p53)Emx1-cre and (Lig4;p53)Emx1-cre tumors, respectively. (E) GSEA indicates
DSBR-deficient tumors are less astroglial and oligodendrocytic in cell signatures
compared to p53Emx1-cre tumors alone. Cahoy dataset was used for glial cell signature
analysis. (F) Comparing (Brca2;p53)Emx1-cre to (Lig4;p53)Emx1-cre identifies Brca2 as
more neuronal and Lig4 more oligodendrocytic.
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identified associated pathways involving neuron development, synapse assembly and
compensatory DNA repair mechanisms significantly upregulated in (Brca2;p53)Emx1-cre
mice (Figure 3-4B). Notable genes enriched in the (Brca2;p53)Emx1-cre gliomas were
tyrosyl-DNA phosphodiesterase 1 (Tdp1), protein kinase, DNA-activated, catalytic
subunit (Prkdc), alkB homolog 2 and alpha-ketoglutarate dependent dioxygenase
(Alkbh2). These genes are all directly involved in repairing various forms of DNA
damage, including single and double strand breaks that prevent neurodegenerative
diseases or cancers [190-192]. In Lig4-deficient samples we observed enrichment of
pathways encompassing regulation of axonogenesis, cell cycle and other DNA damage
response factors (Figure 3-4B). Cyclin D3 (CCND3) and mitogen-activated protein
kinase kinase kinase 1 (MAP3K1) genes were more upregulated in the (Lig4;p53)Emx1-cre
tumors than (Brca2;p53)Emx1-cre (Figure 3-4C). Alterations in CCND3 and MAP3K1
kinases are of particular interest because they have been previously correlated with
pediatric brain tumor development and tumor progression [103, 134, 178, 193]. A direct
comparison of (Brca2;p53)Emx1-cre and p53Emx1-cre tumors through Gene Ontology, which
analyzes gene functions through an enrichment analysis database, revealed additional
DDR pathway genes enriched, specifically in the Brca2-deficient groups:
BRCA1/BRCA2-containing complex subunit 3 (Brcc3), Blm RecQ like helicase or Blm,
RAD51 and Rad18, structural maintenance of chromosomes 1A (SMC1A), and the
chromatin remodeler ATRX (Figure 3-4D). Other genes related to regulation of p53 and
apoptosis were upregulated in (Brca2;p53)Emx1-cre gliomas compensating for loss of p53,
which include; apoptosis enhancing nuclease (AEN), BTG anti-proliferation factor 2
(BTG2), and apoptosis inducing factor mitochondria associated 1(AIFM1) (Figure 3-4D).
These results again highlight how glioma cells gene regulation may be attempting to
compensate for the loss of functions induced by mutations in DSBR and p53-mediated
apoptosis. Conversely, enriched pathways in (Lig4;p53)Emx1-cre compared to p53Emx1-cre
tumors involved RNA related processes. Within the RNA effected pathways the RNA
Binding Motif Protein X-Linked (RBMX) gene was identified. RBMX was discovered in a
genome-wide siRNA screen and was found to be directly associated with BRCA2 and HR
repair [194]. Significantly enriched genes and associated pathways in DSBR gliomas
possibly reveal the reliance of tumor cells on compensatory DNA repair pathways to
survive and proliferate.
Determining the cellular origin for pediatric brain cancers is currently the focus of
extensive research, and in most cases the actual tumor cell of origin remains enigmatic
[195]. It’s unclear if brain tumors originate from stem cell-like populations or from
specific progenitor cell subtypes such as neurons, astrocytes or oligodendrocytes [97]. To
examine the cell of origin in gliomas generated by loss of Brca2 or Lig4 we utilized a
specific transcriptome database developed by a group led by Ben A. Barres (Cahoy) for
specific neural cell types using GSEA [196]. GSEA revealed that DSBR mutant gliomas
displayed varied maturity cellular states of origin with astroglial and oligodendrocytic
cellular populations significantly decreased when compared to control p53Emx1-cre tumors
(Figure 3-4E). Astroglial expression patterns are defined as cultures derived from small
unidentified populations of proliferating glial precursor cells that express several different
astrocyte markers, but appear to have an immature phenotype [196]. In contrast, when
(Brca2;p53)Emx1-cre gliomas were compared to (Lig4;p53)Emx1-cre, Brca2 cKO showed a
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neuronal signature (p<0.001) while Lig4 cKO tended to be oligodendrocytic (p<0.001)
(Figure 3-4F). Histology supports similar heterogenous cell populations effected within
DSBR-deficient mutants, especially increased Olig2 (oligodendrocyte) expression in
(Lig4;p53)Emx1-cre tumors (Figure 3-2B). Thus, Brca2 and Lig4 cKO gliomas have
distinct differences in gene expression patterns with enrichment of unique gene sets for
specific brain cell populations, which may reflect the differential requirements during
neural development [14]. Gene expression analysis suggests that glioma cells with loss of
Brca2 (HR) result in significantly upregulating genes to respond to DNA repair
deficiency, while loss of Lig4 (NHEJ) seem to be more concerned with upregulating
genes to increase tumorigenesis.
Recurrent Chromosomal Rearrangements Characterize DSBR-Deficient HGGs
Chromosomal rearrangements resulting in gene-fusions and DNA copy number
aberrations can lead to gene amplifications which are all common occurrences in many
types of human cancers, including gliomas [90, 141, 177]. Because faulty rearrangements
are due to improperly repaired DSBs [197, 198], we predicted that loss of HR, which is
less error prone, would result in more chromosomal alterations in gliomas than NHEJdeficiency. To identify gene-fusions we utilized a new algorithm developed by the St.
Jude Computational Biology department, called CICERO, that combines RNA-seq with
extensive annotation for gene candidate rankings which help identify driver fusions better
than the traditional canonical exon-to-exon chimeric transcripts [177]. Some of the most
frequent oncogenic fusion events or gene amplifications found in HGGs include MET,
PDGFRα, BRAF, SOX6, PTEN and KRAS (details are discussed as identified below) [80,
90, 199]. Utilizing both transcriptome and whole exome sequencing from mouse tumor
samples we identified various potential gene-fusions and amplifications with unique
structural variants. One of the most common identified fusions, particularly in more than
30% of analyzed (Brca2;p53)Emx1-cre tumors, was Met, which encodes the protein c-MET,
a known tyrosine kinase (Figure 3-5A). The Met fusion partner was most frequently
Capza2. MET fusions are also found in about 5% of pediatric glioblastoma multiforme
and 10% of pHGG cases [199]. In addition, we found higher Met and Pdgfrα
amplifications in the mouse samples when compared to a human glioma dataset (Figure
3-5A, B). Chromosomal abnormalities of Met and Pdgfrα were confirmed using
fluorescence in situ hybridization (FISH) and IHC (Figure 3-5B). Other gene alterations
identified that have been extensively documented to have direct involvement of
neurodevelopment and tumorigenesis were Braf, Sox6, Kras and Pten (Figure 3-5C, D)
[101, 124, 132, 200-202]. BRAF mutations are found in about 10% of pediatric cortical
HGGs and more frequently in rare cancers like pleomorphic xanthoastrocytomas and
anaplastic gangliomas [80, 88]. The specific BRAF V600E mutation, which encodes a
Ras-regulated serine/threonine kinase, was one of the only activating mutations found in
a p53Emx1-cre glioma [201] (Figure 3-5C). Colorimetric IHC analysis and comparison to
human glioma data confirmed the uniqueness of this specific mutation within the sample
set (Figure 3-5C). We also identified overexpression of Sox6 in a many of DSBR
deficient tumors. Sox6 is a transcription factor important for neurodevelopment and its
amplification has been found in human glioma patients [202]. Additionally, the potent
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Figure 3-5. Recurrent chromosomal rearrangements characterize DSBR-deficient
HGGs.
(A) Met gene-fusions were the most common fusion event identified in mouse tumor
samples, particularly in the (Brca2;p53)Emx1-cre group. FISH confirmed amplification of
MET in mouse gliomas. Compared to human glioma samples, mouse tumors had on
average higher overall expression values (FPKM - Fragments Per Kilobase of transcript
per Million mapped reads). (B) Pdgfrα is overexpressed in many mouse HGGs. IHC and
FISH analysis confirm PDGFRα over-expression and amplification, respectively. Pdgfrα
was also more highly expressed in mouse tumor samples than human examples. Scale
bar, 1mm for whole brain sections, 100μm for higher-magnification images. (C)
Structural variants of Braf were found in all tumor groups, including a ZEB2-BRAF
fusion in a (Lig4;p53)Emx1-cre sample. IHC staining identified Braf point mutation V637E
(V600E – human) in a p53Emx1-cre tumor. This mutation was also identified in three
human samples from a previous database. Scale bar, 1mm for whole brain sections,
100μm for higher-magnification images. (D) Sox6, Kras, and Pten are commonly altered
genes in pHGGs and are overexpressed in select mouse gliomas. (E) (Brca2;p53)Emx1-cre
(n = 7) tumors had more overall somatic mutations on average than (Lig4;p53)Emx1-cre (n =
8) tumors from whole exome sequencing (>5 reads per mutant and variant allele
frequency >0.1, p-Value = 0.0006).
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oncogene Kras, was overexpressed in a few of the HGG samples, implicating its role in
assisting in tumorigenesis. Interestingly, Pten, a common tumor suppressor, had
increased expression in about 2/3rds of the glioma samples, which is unexpected for a
tumor suppressor, however overexpression of other tumor suppressors have been
identified in some brain tumors [203]. Lastly, from whole exome sequencing we found
the average number of somatic mutations (single-nucleotide variations) in the
(Brca2;p53)Emx1-cre tumors (~32) was almost three times that of the (Lig4;p53)Emx1-cre
mice (~12) (Figure 3-5E). These data together suggest loss of HR results in
accumulation of more mutations, including gene-fusion alterations known to cause
HGGs. This is likely due to cortical progenitors having to rely primarily on the more
error-prone form of DSBR, NHEJ, during the earliest and most critical time period of
development.
Inhibition of DSBR pathways through inactivation of Brca2 (HR) or Lig4 (NHEJ)
with concurrent inhibition of p53 in the mouse cortex resulted in HGG formation.
Analysis of tumor histology determined glioma classifications and diffusion based on
abnormal cellular morphology including glial specific populations. Further investigation
into tumor gene expression profiles revealed differences in gene dysregulation between
HR- and NHEJ-deficiency. Based on the correlation with DSBR-deficiency and glioma
development, we explored the possible cause of this tumorigenesis by examining
genomic integrity during mouse embryogenesis.
DSBR-Deficiency and p53 Inactivation in Neocortex Result in Selective DNA
Damage Accumulation
To determine if Brca2- or Lig4-deficiency during early cortical development
caused DNA damage, we examined γH2AX in (Brca2;p53)Emx1-cre and (Lig4;p53)Emx1-cre
cortices at different stages of development. During early development at E12.5 and
E15.5, DNA damage accumulation, shown by γH2AX-foci, was quantified in the
neocortex (Figure 3-6A-D). The (Brca2;p53)Emx1-cre mutant mouse had slightly higher
DNA damage at E12.5 than (Lig4;p53)Emx1-cre (Figure 3-6A, B). Even at this early period
of development a subtle difference can be noticed between the location of γH2AX-foci,
with (Brca2;p53)Emx1-cre damage being in the lower SVZ and VZ layers and
(Lig4;p53)Emx1-cre having more damage in the upper MZ, CP and IZ layers. However, the
difference in spatial DNA damage becomes much clearer three days later in
corticogenesis. At E15.5, (Brca2;p53)Emx1-cre γH2AX-foci were noticeably condensed in
the lower or deep cortical layers corresponding to the highly proliferative progenitors
marked by PCNA, suggesting that DSBs resulting from Brca2-deficiency occurred
during replication (Figure 3-6C, D). Conversely, in the (Lig4;p53)Emx1-cre brain at E15.5,
the greatest number of foci were identified and concentrated in the upper most
differentiated cortical cell layers (cortical plate and marginal zone), although marginal
amounts of damage were also found throughout other cortical layers (Figure 3-6C-D).
The difference in the primary location of DNA damage within the cortices of Brca2 and
Lig4 mutant mice is likely due to the specific repair pathway available during particular
stages of cellular development. HR is the primary repair pathway used by the earliest
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Figure 3-6. DSBR-deficiency and p53 inactivation in neocortex result in selective
DNA damage accumulation.
(A) DNA damage, in the form of γH2AX-foci, accumulates more in (Brca2;p53)Emx1-cre
during early embryogenesis at E12.5 than (Lig4;p53)Emx1-cre in the neocortex. PCNA is
representative of high proliferation throughout cortex at this state and side box indicates
cortical layers. Dashed white line indicates approximate division of upper and deep
cortical layers. Red box closeups highlight γH2AX-foci in cortical layers. (B) Total
number of γH2AX-foci quantified in 150μm2 area. N ≥ 3 animals per groups, ≥ 9 images
per group. ****p<0.0001, *p=0.0265. (C) 3 days later in embryonic development at
E15.5 the amount of DNA damage accumulation separates into cortical layered
differences by DSBR mutation. (Lig4;p53)Emx1-cre mice have significantly higher levels of
damage in upper layers, while (Brca2;p53)Emx1-cre mice have more damage in the deep
neocortex. Dashed white line indicates division of upper and deep cortical layers. Red
box closeups highlight γH2AX-foci in cortical layers. Pan-nuclear γH2AX stain may be
indicative of cell death or non-specific background. (D) Number of γH2AX foci
quantified for upper and deep layers and total neocortex combined. Deep layers: 330μm2
area quantified; Upper layers: 200μm2 area quantified; Total all layers: 550μm2 area
quantified. N ≥ 3 animals per groups, ≥ 9 images per group. ****p<0.0001, *p=0.0495.
All graphs represent mean values of replicates. Error bars indicate SEM. Abbreviations:
VZ: ventricular zone, SVZ: subventricular zone, IZ: intermediate zone, CP: cortical plate,
MZ: marginal zone.
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born replicating progenitors (E12.5 and lower E15.5 cells) as they rely on a less errorprone mechanism to reduce risk of producing improperly repaired DNA [3, 4]. Therefore,
it is logical that the majority of damage from Brca2 inhibition (HR-deficiency) would be
identified in the deep highly proliferative subgroup of cells in the VZ, SVZ and IZ [48].
In contrast, NHEJ acts as the major repair pathway in post-mitotic, differentiating and
mature neurons (Upper cells in E12.5/E15.5) [6]. Accordingly, the vast amount of DNA
damage in the Lig4-deficient mice was found in the upper differentiated cortical cell
layers. Surprisingly, the difference in the total amount and location of DNA damage
didn’t directly affect tumor latency or overall survival between either of the two DSBRdeficient mouse models. These findings significantly highlight the importance of proper
DSBR in preventing DNA damage accumulation and gliomagenesis in the developing
cortex.
DNA Damage from DSBR-Deficiency with p53 Inhibition Induces G2/M Checkpoint
To confirm the effect DNA damage has on cortical progenitors, we assessed cell cycle
checkpoint activation. Neural cells in the proliferative region of the ventricular zone (VZ)
undergo interkinetic nuclear migration between E13 and E18, where the cells nuclear
location is reflective of its cell cycle phase [18, 23]. Cells in the S-phase reside at the
basal surface, while cells in the G2/M-phase are located at the apical surface of the VZ,
as illustrated in (Figure 3-7A). Apical cortical progenitors in M-phase can be identified
using the histone H3 phospho-ser10 (pH3) marker. Additionally, we analyzed Tuj1, a
marker for differentiated neurons, but noticed no observable difference between DSBRdeficient mice or controls at E12.5 or E15.5, however it did serve as a useful cortical
layer marker (Figure 3-7B, D). We found a reduction of pH3-immumopositive M-phase
cells only in the (Lig4;p53)Emx1-cre neocortices at E12.5. However, a significant reduction
in both the (Brca2;p53)Emx1-cre and (Lig4;p53)Emx1-cre mutants was observed at E15.5
(Figure 3-7B-E). The lack of apical cortical cells in M-phase indicates an arrest in the
cell cycle at this point, correlative with the high levels of the DNA damage present.
Tumor RNA-seq analysis also identified enrichment of miotic, G2/M checkpoint phase,
genes in both Brca2- and Lig4-deficient gliomas (Figure 3-7F and Figure 3-4D,
respectively). Cell cycle arrest is designed to allow time for DDR and the cell will resist
apoptosis unless it is unable to sufficiently repair the damage. However, the inhibition of
p53 in this model does not allow induction of apoptosis, which accounts for the lack of
cell loss throughout the cortex (data not shown) that we previously identified in mice
with functional p53 (Figure 3-2A, D). The role p53 plays on the cell cycle is
multifaceted as it also serves a critical function in controlling the G1/S-phase checkpoint
[6], however since we inhibited p53 we predicted this checkpoint would subsequently be
inactivated. 5-bromodeoxyuridine (BrdU) incorporation experiments were performed on
E15.5 mice to further examine the G1/S checkpoint in the neocortex. Basal progenitor
cells in the G1/S phase can be identified as positive for BrdU. Staining for BrdU
displayed no significant difference between (Brca2;p53)Emx1-cre and control embryos
(Figure 3-7G). Thus, supporting inactivation of p53 inhibits the ability for the G1/Sphase checkpoint to be activated [204]. Together, these data indicate that loss of DSBR
and p53 inhibition induce high levels of DNA damage from replicative stress in cortical
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Figure 3-7. DNA damage from DSBR-deficiency induces G2/M cell cycle
checkpoint.
(A) Illustration of the interkinetic nuclear migration process of progenitor cells within the
SVZ and VZ as they progress through cell cycle. (B) Apical mitotic cortical progenitors
in M-phase at E12.5 were identified using histone pH3 (Ser10) (white arrows – green
cells). Tuj1 marks for differentiated neurons. (C) Quantification of pH3 positive cells at
E12.5. N ≥ 3 animals per groups, ≥ 9 images per group. ****p<0.0001; n.s., not
significant. (D) Decreased mitotic positive apical progenitors at E15.5 in DSBR mutants
using pH3. Tuj1 indicating cell layers of differentiated neurons. (E) Quantification of
pH3 positive cells at E15.5. N ≥ 3 animals per groups, ≥ 9 images per group.
**p=0.0017; n.s., not significant. (F) Upregulated genes and associated pathways
involved in the G2/M-phase checkpoint in (Brca2;p53)Emx1-cre tumors compared to
p53Emx1-cre controls (Enrichr). (G) BrdU incorporation was used to identify basal cortical
progenitors in G1/S-phase at E15.5. Quantification of total BrdU positive cells in cortical
layers; VZ, SVZ and IZ was also collected. N = 1 animal per group, ≥ 3 images per
group. Graphs represent mean values of replicates. n.s. = not significant Error bars
indicate SEM.
Modified with open access permission. Azzarelli, R., F. Guillemot, and E. Pacary,
Function and regulation of Rnd proteins in cortical projection neuron migration. Front
Neurosci, 2015. 9: p. 19.
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progenitors, which in turn activates the G2/M cell cycle checkpoint. Checkpoint
activation allows sufficient time for errors in DNA repair to occur because of the
coinciding DSBR-deficiency. Thus, these errors produce possible mutations which
accumulate in the developmentally critical progenitor cell population resulting in
increased tumorigenesis.
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CHAPTER 4. H3K27M MODULATES BIVALENT GENE EXPRESSION WITH
DSBR INACTIVATION ACCELERATING GLIOMAGENESIS
Histone H3 mutations are critical events in pediatric high-grade gliomagenesis
occurring in about 50% of cases [80-82]. The most common histone mutation found in
these gliomas is H3K27M, which is identified in about 60% of DIPG and non-brainstem
midline pHGGs [80]. A variety of other mutations are identified with H3K27M gliomas,
however p53 mutations are by far the most frequent (~50%) [80-82]. Since the discovery
of these oncohistones in pHGGs in 2012, the interest in developing representative models
has taken off [81, 82, 154-157]. Recently, Suzanne Baker’s lab created the first (H3.3)
H3K27MLox-stop-Lox conditional knock-in mouse [159, 160]. Their group showed that
neonatal induction of H3K27M with activated PDGFRα and p53 loss accelerated diffuse
brainstem gliomas that recapitulated DIPGs in a mouse model [160]. Using this new
H3K27M mouse, we examined the consequence of this oncohistone in our glioma model
in the context of cortical development, genome instability and cortex-specific
gliomagenesis. In this chapter we discuss the results of expression of the H3K27M
mutation in the context of p53Emx1-cre, (Brca2;p53)Emx1-cre and (Lig4;p53)Emx1-cre.
H3K27M Mutation Produces Global Loss of H3K27me3 and Increases H3K27
Acetylation in Embryos
We assessed what effect H3K27M would have on the DSBR-deficient mice by
breeding with H3K27MLox-stop-lox conditional knock-in mice, resulting in the following
cohorts; (p53;H3K27M)Emx1-cre, (Brca2;p53;H3K27M)Emx1-cre and
(Lig4;p53;H3K27M)Emx1-cre (for simplicity all previous mice generated in chapter 2
without the H3K27M mutation will be considered H3WT). Post-translational
modifications (PTMs) of the histone mutation H3K27M in pHGG and as seen in other
models classically reduce H3K27 tri-methylation (H3K27me3) and in some cases
promote increased H3K27 acetylation (H3K27ac) [147, 160, 163, 205]. Examination of
H3K27me3 expression levels in cortical embryonic tissue at both E12.5 and E15.5
showed a global loss of H3K27me3 in the neocortex of any H3K27M mutant compared
to H3WT embryos, like (Brca2;p53)Emx1-cre. This data confirms H3K27M expression
reprograms the H3K27me3 landscape in the cortex of this model (Figure 4-1A, B). To
our knowledge this is the earliest reported endogenous gene activation of H3K27M in a
murine model [154, 156, 157, 160]. Methylation at H3K27M is generally associated with
gene silencing and acetylation is indicative of gene activation [147, 206]. We also found
a modest increase of H3K27ac in upper and deep cortical layers of the H3K27M mutant
mice (Figure 4-1C). Thus, activation of the H3K27M mutation via Emx1-cre
recapitulates the consequence of this histone mutation seen in most other scenarios,
independent of DSBR-deficiency.
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Figure 4-1. H3K27M mutation produces global loss of H3K27me3 and increased
H3K27acetylation in embryos.
(A) H3K27me3 is significantly reduced in all H3K27M mutant neocortices at E12.5 (left
panels) and E15.5 (right panels) compared to (Brca2;p53)Emx1-cre mice. (B) All mouse
cohorts containing H3K27M displayed almost complete abolition of H3K27me3 at E15.5
throughout the cortex. (C) H3K27acetylation is increased in H3K27M mutants compared
to (Brca2;p53)Emx1-cre neocortices at E15.5 in upper and deep cortical layers (between
white hash marks and closeups). Both colorimetric (left panels) and immunofluorescent
(right panels) staining were performed for H3K27ac expression.
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H3K27M Accelerates Glioma Formation and Increases Tumor Diffusion
To determine the impact of the H3K27M mutation on tumorigenesis we aged and
monitored (p53;H3K27M)Emx1-cre, (Brca2;p53;H3K27M)Emx1-cre and
(Lig4;p53;H3K27M)Emx1-cre mice for tumors. Remarkably, we found a pronounced
acceleration of tumor occurrence correlating with a decrease in survival (Figure 4-2A).
(p53;H3K27M)Emx1-cre mice develop HGGs about 1.5-2 months more quickly than
(Brca2;p53)Emx1-cre or (Lig4;p53)Emx1-cre mice and at an incidence rate of ~69%. The
addition of DSBR-deficiency further decreased survival with (Lig4;p53;H3K27M)Emx1-cre
mice dying on average about two months earlier than (p53;H3K27M)Emx1-cre mutants and
(Brca2;p53;H3K27M)Emx1-cre mice having the lowest tumor-free survival at ~6 months.
(Brca2;p53;H3K27M)Emx1-cre mutants not only succumbed to gliomas quicker than
(Lig4;p53;H3K27M)Emx1-cre mice, by about 2 weeks, but also had a much higher
incidence of ~90% compared to ~67%, respectively. On average the addition of H3K27M
with DSBR-deficiency accelerated tumorigenesis by about 4 months compared to their
H3WT counterparts. Phenotypically, mice carrying the H3K27M mutation were smaller
in overall size by about 30% less body weight at weaning age (21 days postnatal)
compared to littermate controls, indicating a defect in early growth development (Figure
4-2B). Noticeably, the size discrepancy declined as mice aged into adults. In addition to
initial delay in growth, mice with the H3K27M mutation also demonstrated extreme
hyperactivity throughout their lifespan. This hyperactive behavior progressively slowed
down within the last few weeks of life, with mice noticeably losing their fight-or-flight
reactions and becoming slouched/hunched, dehydrated, almost immobile and moribund.
These signs of mortality and additionally cranial swelling or a “domed head,” are
frequent among all of the glioma cohorts. The unique characteristic effects of H3K27M
mice highlight some of the underlying problems associated with this mutation and the
potential mechanisms that make it such a potent oncogene.
To determine the impact of expressing the H3K27M mutation in DSBR mutant
background we assigned tumor diffusion scores by analyzing H&E and PCNA
immunohistochemistry (Figure 4-2C, D). Comparatively, all H3K27M tumors exhibited
considerably higher diffusion scores (4 or 5) by more than 40% matched to H3WT
gliomas. Both (Brca2;p53;H3K27M)Emx1-cre and (Lig4;p53;H3K27M)Emx1-cre gliomas were
highly diffuse and infiltrative with increased cellularity and proliferative cell populations
throughout almost the entire adult mouse cortices. Individually, (Lig4;p53;H3K27M)Emx1cre
mice displayed the greatest tumor cell diffusion, with 56% of analyzed tumors having
a diffusion score of 5 compared to (Brca2;p53;H3K27M)Emx1-cre gliomas that only had
17% with a score of 5 but 44% with a score of 4 (Figure 4-2C). Although
(Lig4;p53;H3K27M)Emx1-cre mice had the highest overall tumor cell diffusion, PCNA
quantification identified significantly more proliferative positive cells in
(Brca2;p53;H3K27M)Emx1-cre brains (Figure 4-2D), reflective of highly concentrated
areas of PCNA in these mice (Figure 4-2C). When determining diffusion score, we
based the analysis on the total area PCNA positive cells spread throughout the brain.
Locationally, gliomas with H3K27M were similar to H3WT gliomas in that both
primarily occur in the cortex and olfactory bulb with some increased diffusion into
olfactory cortex, thalamus, hypothalamus, hippocampus and midbrain regions. This data
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Figure 4-2. H3K27M accelerates glioma formation and increases tumor diffusion.
(A) Kaplan-Meier survival analysis displays decreased survival of mice with H3K27M.
p53Emx1-cre (n = 15/44), (Brca2;p53)Emx1-cre (n = 43/97), (Lig4;p53)Emx1-cre (n = 45/108),
(p53;H3K27M)Emx1-cre (n = 23/33), (Brca2;p53;H3K27M)Emx1-cre (n = 65/72) and
(Lig4;p53;H3K27M)Emx1-cre (n = 68/102); Tumor incidence: (n = # mice died of glioma /
# total mice), ****p < 0.0001, n. s. = not significant (p = 0.2326). (B) Graph displaying
the difference in mouse weights at P21 in littermate controls showing decrease in mutants
containing H3K27M, nondependent on gender. ****p<0.0001, *p=0.0280. (C) Glioma
diffusion scores increased considerably in H3K27M brain tumors. H&E and PCNA
staining were used to determine diffusion score. White dashed lines outline primary
tumor(s). PCNA indicates tumor cell proliferation and diffusion; numbers in bottom right
denote diffusion score of representative images of HGGs. Least diffuse (1) to highest (5).
Percentage of tumors analyzed with determined diffusion score. are shown. Scale bar,
~1mm. p53Emx1-cre (n = 4), (Brca2;p53)Emx1-cre (n = 16), (Lig4;p53)Emx1-cre (n = 9),
(p53;H3K27M)Emx1-cre (n = 3), (Brca2;p53;H3K27M)Emx1-cre (n = 18) and
(Lig4;p53;H3K27M)Emx1-cre (n = 9). (D) PCNA quantification of all glioma mouse
samples. ****p<0.0001, ***p=0.0025 (E) Reduction of H3K27me3 carries through
development into tumors with H3K27M, independent on DSBR-deficiency. Scale bar,
1mm for whole brain sections.
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suggests the combinatorial effect of the H3K27M mutation increased tumor diffusion and
probable overall glioma grade, supporting its known role in driving HGG formation in
patients and other models [81, 82, 155, 160]. All H3K27M mutant tumors observed
contained similar amounts of H3K27me3 loss (Figure 4-2E), indicating the H3K27M
mutation and its effect on PTMs is present throughout development into tumorigenesis in
our model. Taken together, we observed the addition of H3K27M increases tumor
incidence and diffusion and decreases survival, especially when DNA repair is
compromised by concomitant inhibition of HR or NHEJ.
H3K27M Enhances DNA damage Accumulation in the Mouse Neocortex
We hypothesized that the histone mutation may affect chromatin conformation
leading to increased DNA damage susceptibility as part of the mechanism leading to
gliomagenesis. To assess the levels of DNA damage introduced by the expression of the
H3K27M mutation in DSBR-deficient mutants, we examined γH2AX staining to quantify
levels of DSBs during corticogenesis. At E12.5, the expression of the H3K27M mutation
in the (Brca2;p53;H3K27M)Emx1-cre mouse resulted in a significant increase in γH2AXfoci compared to all other cohorts, suggesting H3K27M is further inhibiting DNA repair
in the early stages of cortical development where cells are highly replicative (Figure
4-3A, B). Surprisingly, (Lig4;p53;H3K27M)Emx1-cre mice did not result in more DNA
damage at E12.5 than (Lig4;p53)Emx1-cre embryos, indicating a preferential importance of
H3K27M and HR in the earlier stages of embryogenesis. We did observe a subtle cortical
cell layer difference after DNA damage that was previously identified at E12.5 between
Brca2- deficient (lower) and Lig4-deficient (upper) mice (Figure 4-3A and 3-6A). It
appears that (Lig4;p53;H3K27M)Emx1-cre mice have increased DNA damage in the upper
layers, while (Brca2;p53;H3K27M)Emx1-cre γH2AX-foci are distributed throughout the
proliferative cells at this stage (Figure 4-3A). Most intriguingly, at the E12.5
developmental stage, there was a significant amount of γH2AX-foci present in
(p53;H3K27M)Emx1-cre cortices (Figure 4-3A, B). These mice have intact DSBR, but
sustained significantly more DNA damage at E12.5 than (Lig4;p53)Emx1-cre mice,
suggesting that the histone mutation and its consequential effect on the chromatin
conformation may be playing a role in preventing or delaying appropriate DNA repair
[207-209]. Further, we observed slightly lower amounts of DNA damage in H3K27MEmx1cre
(functional p53) neocortices at E12.5 compared to (p53;H3K27M)Emx1-cre (data not
shown), indicating that p53-mediated DNA damage response may be regulating repair.
At E15.5 the amount of γH2AX-foci in (p53;H3K27M)Emx1-cre mice remained at relatively
the same level, with only a slight increase in the deep cortical layers (Figure 4-3C, D).
This highlights the importance of H3K27M in the highly proliferative cortical cell
population present in the lower layers. The addition of H3K27M with the DSBRdeficient mutants further exacerbated the cortical spatial difference of DNA damage that
we previously identified between (Brca2;p53)Emx1-cre and (Lig4;p53)Emx1-cre mice at
E15.5. (Brca2;p53;H3K27M)Emx1-cre embryos displayed significantly more γH2AX-foci
in deep cortical layers. While (Lig4;p53:H3K27M)Emx1-cre not only had significantly more
DSBs in the upper layers but resulted in the greatest amount of DNA damage
accumulation total throughout the entire cortex at E15.5 (Figure 4-3D). Interestingly,
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Figure 4-3. H3K27M enhances selective DNA damage accumulation in the mouse
neocortex.
(A) DNA damage (γH2AX-foci) increases in (p53;H3K27M)Emx1-cre and
(Brca2;p53;H3K27M)Emx1-cre mice neocortex at E12.5. PCNA is representative of high
proliferation throughout cortex at this state. Side box and dashed white line indicates
approximate division of upper and deep cortical layers. Lower panels have DAPI
subtracted to highlight γH2AX-foci. (B) Total number of γH2AX-foci quantified in
150μm2 area. N ≥ 3 animals per groups, ≥ 9 images per group. *p<0.0306, *p<0.0150,
****p<0.0001, n.s. = not significant. (C) DNA damage is cumulative at E15.5 in
H3K27M mutants with selective differences in cortical layers. (Lig4;p53;H3K27M)Emx1cre
mice have significantly higher levels of damage in upper layers, while
(Brca2;p53;H3K27M)Emx1-cre mice have more damage in the deep neocortex. Dashed
white line indicates division of upper and deep cortical layers. Lower panels have DAPI
subtracted to highlight γH2AX-foci. Pan-nuclear γH2AX stain may be indicative of cell
death or non-specific background. (D) Number of γH2AX foci quantified for upper and
deep layers and total neocortex combined. Deep layers: 330μm2 area quantified; Upper
layers: 200μm2 area quantified; Total all layers: 550μm2 area quantified. N ≥ 3 animals
per groups, ≥ 9 images per group. ****p<0.0001, ***p=0.0001, **p=0.0065,
**p=0.0031, *p=0.0446, n.s. = not significant. All graphs represent mean values of
replicates. Error bars indicate SEM. Abbreviations: VZ: ventricular zone, SVZ:
subventricular zone, IZ: intermediate zone, CP: cortical plate, MZ: marginal zone.
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even with the significant increase of γH2AX-foci in the deep cortical layers of
(Brca2;p53;H3K27M)Emx1-cre mice, this did not result in enough damage to change the
total amount compared to (Brca2;p53)Emx1-cre. These data together, suggest that H3K27M
effect on genome stability aligns with the importance of the particular DSBR pathway at
the developmental time period which it is the preferred repair mechanism. In short,
H3K27M increases DNA damage with Brca2-deficency (HR) in the deep earlier born
cortical progenitors, while having a similar effect with Lig4-deficency (NHEJ) in the
upper, more differentiated, cell populations.
DNA Damage from H3K27M Induces G2/M Checkpoint in Cortical Progenitors
With the observed increase in DNA damage from mice carrying the H3K27M
mutation we further investigated the effect of this on G2/M checkpoint activation using a
similar method as described previously utilizing the mitotic phospho-H3 marker in the
neocortex. All H3K27M groups displayed significantly less mitotic positive apical
cortical progenitors compared to control and (Brca2;p53)Emx1-cre mice at E12.5 (Figure
4-4A). Interestingly, (Brca2;p53;H3K27M)Emx1-cre significantly activated the G2/M
checkpoint, likely reflecting the increased DNA damage from the histone mutation. This
same effect was not seen in (Lig4;p53:H3K27M)Emx1-cre mice as these displayed almost
identical amounts of pH3 positive cells as (Lig4;p53)Emx1-cre cortices, aligning with the
similar location and amount of DNA damage seen in both of these mutants at E12.5 and
E15.5 (Figure 4-4B). At E15.5 the greatest G2/M checkpoint activation in apical
progenitors was observed in the (Brca2;p53;H3K27M)Emx1-cre cortex (Figure 4-4B),
suggesting again the lower earlier born cortical progenitors are the greatest effected by
extra damage from H3K27M. Work done by Wieland Huttner’s group and others have
shown that directly reducing H3K27me3 on the Eomes locus, a key basal progenitor
regulator of Tbr2 in NSCs of mice, not only reduces the number of Tbr2 positive cells in
the cortex but also directly decreases the amount of basal progenitors undergoing mitosis
[106, 210, 211]. Interestingly, a small population of basal progenitors in the SVZ
undergoing mitosis also stain positive for pH3. We found in the H3K27M mice, where
we show a global decrease in cortical H3K27me3 (Figure 4-1A, B), that this decrease in
H3K27me3 directly correlates the loss of basal mitotic positive cells and Tbr2 positive
cells (Figure 4-4B, C). The loss of Tbr2-positive cells was measured throughout the IZ,
SVZ and VZ cortical layers in H3K27M mice compared to controls (Figure 4-4C). This
suggests that epigenetic modifications, like repressive histone methylation, contribute to
regulation of the developing neocortex. Lastly, BrdU incorporation was again measured
to identify potential differences in basal progenitors undergoing the G1/S-phase transition
at E15.5 in the H3K27M mutants (Figure 4-4D). Analyzing both the intermediate zone
and all other BrdU positive cells individually found no significant reduction or effect
from the histone mutation, which further supports that loss of p53 prevents activation of
the G1/S checkpoint. Taken together, these data indicate H3K27M further exacerbates
DNA damage in the neocortex which induces the G2/M checkpoint in the basal and
apical progenitor cells. The delay and prolongation of the cell cycle at this critically
important neural expansion time period suggest that epigenetic modifications from
H3K27M contribute to genome instability, improper cortical development and ultimately
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Figure 4-4. DNA damage from H3K27M induces G2/M checkpoint in cortical
progenitors.
(A) Apical cortical progenitors in M-phase at E12.5 were identified using histone pH3
(Ser10) (green) and neuronal differentiation marker Tuj1 (red) was used for cortical layer
identification. (n ≥ 3 animals per groups, ≥ 9 images per group). ****p<0.0001, n. s. =
not significant. (B) G2/M checkpoint activation at E15.5 in basal (white arrows) and
apical (red arrows) progenitors were analyzed and quantified individually. (n ≥ 3 animals
per groups, ≥ 9 images per group). *p<0.05, **p<0.01. (C) Tbr2 identifies intermediate
basal progenitors progressing through the VZ, SVZ and IZ at E15.5. Tbr2 positive cells
are reduced in H3K27M mutants. (n = 1 animal per group, ≥ 3 images per group.
*p=0.0323, ***p=0.0005. (D) BrdU incorporation was used to identify basal cortical
progenitors in S-phase proliferating at E15.5. BrdU positive cells were quantified in the
IZ only or all lower layers together (VZ, SVZ, and IZ). (n = 1 animal per group, ≥ 3
images per group. n. s. = not significant. All graphs represent mean values of replicates.
Error bars indicate SEM.
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accelerated tumorigenesis.
H3K27M Gliomas Exhibit Unique Gene Expression Changes That Recapitulate
Signatures Identified in pHGGs
We performed RNA-sequencing on (p53;H3K27M)Emx1-cre,
(Brca2;p53;H3K27M)Emx1-cre and (Lig4;p53:H3K27M)Emx1-cre gliomas to assess gene
expression changes that may underpin the function of H3K27M driven malignancy
effects. Unsupervised hierarchical clustering of the most differentially expressed (up- or
downregulated) genes revealed H3K27M tumors group together with distinct gene
expression patterns compared to tumors without the histone mutation (H3WT) (Figure
4-5A, B). Mouse gliomas with H3WT displayed less consistent grouping, suggesting
H3K27M may be reducing tumor heterogeneity (Figure 4-5A). Examination of genes
with the greatest differential expression uncovered uniquely enriched gene sets based on
the presence or absence of H3K27M (Figure 4-5B). Plag1 (oncogene), Hopx
(neurodevelopment), Eya4 (DNA repair) and Slit2 (axon guidance and neuronal
migration) are among the most significantly upregulated in H3K27M tumors and show
clear expression shift from H3WT gliomas, as shown in violin plots (Figure 4-5B, upper
panel). Conversely, some of the most downregulated genes in H3K27M gliomas were
Irx3/5 (embryonic neural development), Foxd2 (neurodevelopment), Gata6 (cell
differentiation and bone morphogenetic protein (BMP) signaling), Hoxa7 (embryonic
development), En1/2 (embryonic development) and Six2 (proliferation and migration)
(Figure 4-5B, lower panel). Many of these genes, including Plag1, Eya4, Slit1/2 and
Gata6, are identified and emphasized as prominent factors in other similar H3K27M
models [155, 157, 160, 162]. One particular group of downregulated genes from
H3K27M signatures are the Hoxa gene cluster (Hoxa2-7, and 10), a subset of homeobox
genes directly involved in transcriptional regulation and differentiation (Figure 4-5B, C)
[212]. Downregulation of homeobox genes indicates H3K27M is potentially repressing
developmentally important genes to favor tumorigenesis.
When examining the relative change in gene expression between gliomas
containing the H3K27M mutation and those without the mutation (H3WT), we found a
greater overall average gene expression in the gliomas carrying H3K27M, with 658 genes
showing increased expression and 367 displaying decreased expression (Figure 4-5D).
This aligns with evidence supporting H3K27M mutations being linked to increased gene
expression due to the global loss of the repressive H3K27me3 mark [213]. Amongst the
most upregulated genes in H3K27M gliomas were oncogenes Egfr and Lin28b, tumor
suppressor Cdk6 , and Eya1/2, which are linked to DNA repair (Figure 4-5E). Consistent
with the known role that the polycomb repressive complexes, PRC1 and PRC2, play in
modulating H3K27me3 [150, 213, 214], specific components of these complexes were
identified through the ChIP-sequencing Enrichment Analysis (ChEA) database [215].
Upregulated genes of these complexes in H3K27M gliomas were Ring1b and Bmi1
(PRC1) and Ezh2, Suz12, and Jarid2 (PRC2) (Enrichr - ChEA) [176] (Figure 4-5F).
Interestingly, PRC1 components have also been linked to stable repression of
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Figure 4-5. H3K27M gliomas exhibit unique gene expression changes that
recapitulate signatures identified in pHGGs.
(A) Unsupervised clustering of genes identified by ANOVA of all HGG groups reveals
H3K27M tumor samples increasingly cluster by genotypes in a heatmap. p53Emx1-cre (n =
6), (Brca2;p53)Emx1-cre (n = 16), (Lig4;p53)Emx1-cre (n = 10), (p53;H3K27M)Emx1-cre (n = 3),
(Brca2;p53;H3K27M)Emx1-cre (n = 18) and (Lig4;p53;H3K27M)Emx1-cre (n = 9). False
discovery rate cutoff <0.05, p<0.0001 (B) Heatmaps and violin plots showing the
average RNA-seq expression signal for the most up- and downregulated genes. The width
of each violin displays how common expression levels are, with the widest portion
corresponding to the mode average. Unpaired student t-test (upregulated; 3.05x10-39),
(downregulated; 1.69x10-90). (C) Heatmap showing unsupervised clustering of all Hox
genes expression comparing all H3K27M and H3WT gliomas. Hoxa genes, highlighted
in red box, with higher expression in H3WT tumors. (D) MA-plot graphs the relative
change in gene expression between gliomas containing the H3K27M mutation and those
without it (H3WT). Genes meeting a LogFC change of 0.5 and a p-value of 0.05 are
labelled in blue, while those with no significant change are black. There are 658 genes
upregulated and 367 downregulated. (M: LogFC and A: Average Log Expression). (E)
Volcano plot displays the change in gene expression compared to significance of
expression change of all H3K27M tumor samples compared to all H3WT samples with
representative gene names indicated. (F) Enrichr analysis indicates significantly
associated enriched pathways of H3K27M upregulated genes. ChEA – ChIP; PRC1/2
upregulated targets and known binding partners of the genes in these two complexes.
PANTHER; axon guidance affected via Slit/Robo pathway. Gene Perturbations; models
relevant to H327M mutations with other common upregulated genes. (G) GSEA using
the most upregulated genes from all the H3K27M mouse gliomas applied to a gene set
for a H3K27M human sample that was identified from the gene perturbations database
(H3F3A K27M GSE34824). Heatmap shows the relative expression of the top 27 genes.
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Hoxa genes [216]. We found key Slit-Robo pathway genes (Slit1/2 and Robo1/2) were
upregulated in H3K27M tumors which directly alter axon guidance, neuronal
systems/development and netrin-1 signaling (identified through the PANTHER database,
which classifies proteins and correlating genes) [217] (Figure 4-5F). Using another
database that looks at RNA expression profiles from transcription factor perturbations in
thousands of cell lines and tissues (GEO Up) [218], we uncovered a high overlap of
highly expressed genes in other H3K27M related samples compared to the most
upregulated genes in the H3K27M gliomas (Figure 4-5F). These included human patient
samples with mutations in H3G34R (recurrent histone mutation), PDGFRα (frequently
overexpressed in pHGGs) and HMGA2 (epigenetic modifier) and mouse model samples,
like an EZH2 KD. Furthermore, GSEA showed that the most upregulated genes from the
H3K27M tumors were significantly enriched in a H3K27M human sample that we
identified from the gene perturbations database (H3F3A K27M GSE34824), which was
one of the original pHGG samples Nada Jabado’s group discovered to have common
histone mutations (Figure 4-5F, G) [82]. From this we identified a unique subset of
shared upregulated genes, including Vcam1 (vascular cell adhesion molecule-1), Agt
(angiotensinogen) Pbx3 (pre-B-cell leukemia homeobox), Peg3/10 (common abnormal
expression in gliomas), Id4 (inhibitor of differentiation 4 – frequently overexpressed in
gliomas), Ndn (necdin – associated with Prader-Willi syndrome), Bmi1 (proto-oncogene),
Slit2 and Eya1/2/4. All of these genes have been shown to play important roles in
gliomagenesis and/or neurodevelopment [219-229]. This data taken together, suggest
gene expression changes associated with H3K27M in a glioma mouse model recapitulate
H3K27M signatures found in pediatric patient HGGs and these signatures display
downregulation of developmentally important Hoxa genes and upregulation of
tumorigenic genes that ultimately contribute to accelerated glioma formation.
H3K27M Increases Glioma Cellularity and Implicates Cell of Origin Signatures
Histological analysis was performed to examine differences between H3K27M
and H3WT tumors for common glioma cell signatures. Because pHGGs are largely
heterogenous, varying in cellular composition from oligodendrocytic to astrocytic and
even neuronal signatures, we used Olig2 and GFAP markers in attempt to classify mouse
gliomas based on predominant cellular populations within tumors. Surprisingly, only
(Brca2;p53;H3K27M)Emx1-cre tumors displayed robust Olig2 expression compared to all
other gliomas, including (Lig4;p53;H3K27M)Emx1-cre (Figure 4-6A, B), suggesting
H3K27M is driving more of an effect on oligodendrocytes when combined HRdeficiency. However, expression of GFAP was significantly increased in both
(Brca2;p53;H3K27M)Emx1-cre and (Lig4;p53;H3K27M)Emx1-cre tumors compared to their
H3WT complements, indicating H3K27M is additionally affecting astrocytic populations.
To further analyze the glial cell differences observed between H3K27M and H3WT
tumors we utilized GSEA and the Cahoy database again, which is specific for neural cell
signatures (Figure 4-6C). This analysis revealed all H3K27M gliomas to have significant
upregulation of genes similar to mature astrocytic signatures, while H3WT tumors match
more closely with immature astroglial cell populations. This suggests H3WT tumors may
originate from less mature progenitor cell populations than H3K27M gliomas.
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Figure 4-6. H3K27M increases glioma cellularity and implicates cell of origin
signatures.
(A) H3K27M gliomas display distinct increases in Olig2 and GFAP expression compared
to H3WT tumors. (B) Quantification of total Olig2 and GFAP positive cells throughout
adult mouse brain. *p<0.03, **p=0.0020, ****p<0.0001. (C) GSEA identified all
H3K27M gliomas associate with more astrocytic and less astroglial signatures compared
to H3WT (Cahoy database). Upregulated genes in H3K27M tumors also associated with
astrocyte differentiation and affected kinase cascades through Gene Ontology for
Biological Processes pathways. Length of bar indicates p-value (D) GSEA of Gene
Ontology (GO) for Central Nervous System showed overlapping gene profiles with
upregulated H3K27M tumor samples for neuronal development and axon guidance along
with BioPlanet pathways. Length of bar indicates p-value.
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Furthermore, gene ontology pathways for biological processes uncovered similar gene
association with astrocyte differentiation, primarily driven by upregulation of tumor
suppressor Cdk6, in H3K27M tumors (Figure 4-6C) [230]. Additional upregulation of
kinase cascade related genes (Egfr, Fgfr2, Ntrk2 and Alk), which are frequently altered in
pediatric HGGs, were identified from same gene ontology for the H3K27M tumors [90,
103, 129]. Specifically, NTRK and ALK, are both tyrosine receptor kinases that have been
implicated as oncogenic drivers due to their frequent chromosomal rearrangements
leading to gene-fusions [231, 232]. Lastly, GSEA for gene ontology in the central
nervous system and the NIH’s database for human pathways (BioPlanet) identified
overlapping gene enrichment in H3K27M tumors with neuronal development and axon
guidance (Figure 4-6D) [233]. This suggests that H3K27M additionally effects a subset
of mature neurons during gliomagenesis. Collectively, these data support that H3K27M
drives similar heterogenous histopathology to human glioma cell signatures, but indicates
that possible differences in cell of origins with DSBR-deficiency exist. H3K27M with
loss of NHEJ implicate more mature astrocytes and neurons as targeted cells, while HRdeficiency associate a mixed glial population with a large population of oligodendrocytes
also effected.
H3K27M Differentiates DSBR-Deficient Gliomas by Unique Gene Expression
Patterns that Effect Neural Development
To better understand the implications of how H3K27M impacts glioma gene
expression in relation to DSBR, we directly compared (Brca2;p53;H3K27M)Emx1-cre and
(Lig4;p53;H3K27M)Emx1-cre RNA-seq data. Unsupervised clustering of the top 331 most
differentially expressed genes revealed distinct hierarchical grouping between tumor
samples except for two (Lig4;p53;H3K27M)Emx1-cre gliomas, which still appeared to share
similar expression patterns with their genotypes (Figure 4-7A). Additionally, we
observed an overall increase in average gene expression in (Lig4;p53;H3K27M)Emx1-cre
(data not shown), including kinases like cyclin dependent kinase 9 (Cdk9), Alk receptor
tyrosine kinase, and stem-cell factor Sox9. Chromosomal rearrangements are common
genetic alterations of Alk resulting multiple different fusion genes in gliomagenesis [231].
Interestingly, a well-known tumor suppressor, cyclin dependent kinase inhibitor 2a
(Cdkn2a), was downregulated in (Lig4;p53;H3K27M)Emx1-cre tumors [132]. It has been
shown various Cdkn genes are dysregulated by the H3K27M mutation [90, 155]. GSEA
using the KEGG axon guidance gene list suggests genes associated with axon guidance,
like Slit and Robo, were upregulated in (Lig4;p53;H3K27M)Emx1-cre (Figure 4-7B, C),
suggesting the role these genes may play in assisting in neural cell proliferation during
gliomagenesis [234]. Direct comparison of (Lig4;p53;H3K27M)Emx1-cre to (Lig4;p53)Emx1cre
, identified a subgroup of protein tyrosine phosphatase (Ptp) genes, Ptpru, Ptprn,
Ptpn5, that were upregulated in (Lig4;p53;H3K27M)Emx1-cre (Figure 4-7C). PTPs are
known to be involved in regulation of a variety of cellular processes including cell
growth, differentiation, mitotic cycle, oncogenic transformation, and glioma biology
[129, 235, 236], indicating a tumorigenic advantage with H3K27M expression. We found
upregulated genes in (Brca2;p53;H3K27M)Emx1-cre are associated with enriched pathways
for cell differentiation and cell-matrix adhesion which may be assisting in tumor cell
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Figure 4-7. H3K27M differentiates DSBR-deficient gliomas by gene expression
patterns that effect neural development.
(A) Unsupervised clustering of top 331 most differentially expressed genes between
(Lig4;p53;H3K27M)Emx1-cre and (Brca2;p53;H3K27M)Emx1-cre tumor samples revealed
distinct hierarchical grouping with increased gene expression patterns in
(Lig4;p53;H3K27M)Emx1-cre. (LogFC>1.0, p<0.05, Avg. exp. >1.0). (B) GSEA shows
upregulation of axon guidance in (Lig4;p53;H3K27M)Emx1-cre gliomas (KEGG). (C) Slit,
Robo and Ptp gene groups are highly upregulated in (Lig4;p53;H3K27M)Emx1-cre gliomas
compared to (Lig4;p53)Emx1-cre. (D) Upregulated genes in (Brca2;p53;H3K27M)Emx1-cre
are associated with enriched pathways for cell differentiation and cell-matrix adhesion.
BMP stimulus, DNA repair and epithelial cell proliferation were also upregulated
compared to (p53;H3K27M)Emx1-cre. (Enrichr; Gene Ontology Biological Processes). (E)
Gene expression comparison of all cohorts either Lig4 or Brca2 null. Upregulation of
neuron projection guidance and cell fate commitment were observed in all Lig4Emx1-cre
tumors. (GSEA; Gene Ontology). (F) Synaptophysin (neural synaptic vesicle marker) is
substantially reduced in (Brca2;p53;H3K27M)Emx1-cre tumors and is mostly retained in
Lig4-deficient samples. Graph depicts RNA-seq tumor gene expression by FPKM. IHC
closeups highlight the tumor specific loss of synaptophysin. Scale bar; 1mm.
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diffusion (Figure 4-7D). Gene ontology pathways revealed BMP stimulus, DNA repair
and epithelial cell proliferation were also upregulated in the (Brca2;p53;H3K27M)Emx1-cre
cohort compared to (p53;H3K27M)Emx1-cre (Figure 4-7D). Activation of BMP signaling
has been linked to ACVR1 (ALK2) mutations in pHGGs [90]. When comparing all
gliomas of either Lig4- or Brca2-deficiency, not dependent on H3K27M, there is a clear
enhanced expression pattern of neuron projection guidance and cell fate commitment
genes in the Lig4-deficient tumor samples from a GSEA gene ontology dataset (Figure
4-7E). This suggests that inhibition of NHEJ may affect a more mature neuron committed
cell population in glioma development. Further, expression of synaptophysin, a neural
synaptic vesicle marker, displayed robust expression throughout the cortex of both
(Lig4;p53)Emx1-cre and (Brca2;p53)Emx1-cre mice but was only slightly reduced in glioma
tissue of (Brca2;p53)Emx1-cre (Figure 4-4F). However, a dramatic loss synaptophysin can
be seen in highly diffuse tumors of (Brca2;p53;H3K27M)Emx1-cre and to a much lesser
extent in (Lig4;p53;H3K27M)Emx1-cre, suggestive of a more neuronal signature when
H3K27M is combined with Lig4-deficiency. RNA-seq expression levels for
synaptophysin supported this. Thus, H3K27M appears to drive more dependent
differential gene expression in Lig4-deficient gliomagenesis, than Brca2, with substantial
upregulation of neuron specific developmental pathways, including axon and neuron
projection guidance and commitment to cell fate.
H3K27M Alters HGG Gene Expression and Identifies Potential Gene-Fusions
We previously found common oncogenic gene-fusion events in HR- or NHEJdeficient mouse tumor samples, using a newly developed algorithm, CICERO [177]
(Figure 3-5). Thus, we were interested in examining the effect H3K27M would have on
such biological phenomena. In (Brca2;p53;H3K27M)Emx1-cre tumors we identified a
variety of gene-fusions, including Tpm3-Ntrk1 (Ntrk are common fusion-genes in
pHGGs), Cux1-Tex11 (Cux1 is a haploinsufficient tumor suppressor that occasionally
fuses with FGF1), Sox6-Def8 and one involving Hmgb1 (high mobility group gene
involved in chromatin remodeling and DNA repair) [90, 202, 237, 238]. In addition to
gene-fusions we uncovered many gene amplifications that carry potential to be genefusions in H3K27M gliomas. Two of which were growth factor receptors, EGFR and
FGFR2, both known to play significant roles in cancer development [126, 127, 130, 132],
were amplified at rates of 75% (Egfr) and 90% (Fgfr2) in H3K27M tumors compared to
20% (Egfr) and 50% (Fgfr2) in H3WT (Figure 4-8A). Other possible amplified genefusions occurred in genes important for regulating neurogenesis and differentiation, such
as Sox6 and Lin28b (Figure 4-8B). Interestingly, H3K27M tumors had decreased
expression of the tumor suppressor Pten compared to H3WT and more specifically
(Brca2;p53;H3K27M)Emx1-cre gliomas had significant loss of the proto-oncogene Kras
(Figure 4-8C), suggesting the involvement of other key drivers of tumorigenesis.
Another unique finding within the (Brca2;p53;H3K27M)Emx1-cre tumors was that they
carried about half the amount of average somatic mutations, determined by whole exome
sequencing, as the counterpart tumors without H3K27M (Figure 4-8D), indicative of
both the decreased tumor free survival age of these mice and that H3K27M pHGGs
generally possess fewer overall mutations. (Brca2;p53;H3K27M)Emx1-cre mice succumbed
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Figure 4-8. H3K27M alters HGG gene expression causing potential gene-fusions.
(A) Potential gene-fusions Egfr and Fgfr2 have higher expressions when H3K27M is
present in gliomas. FISH analysis confirmed cellular expression. (EGFR – red,
chromosome 11 control probe - green and FGFR2 – red, chromosome 7 control probe green). (B) Sox6 and Lin28b display gene amplifications in H3K27M gliomas. (C) Pten
and Kras expression are decreased in H3K27M tumors. Kras is specifically reduced in
(Brca2;p53;H3K27M)Emx1-cre. (D) (Brca2;p53)Emx1-cre (n = 7) tumors had more overall
somatic mutations on average than (Brca2;p53;H3K27M)Emx1-cre (n = 7) tumors from
whole exome sequencing (>5 reads per mutant and variant allele frequency >0.1, p-Value
= 0.0111).
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to gliomas on average two months more quickly than (Brca2;p53)Emx1-cre mice (Figure
4-2A), allowing less time for somatic mutations to accumulate in the H3K27M group.
These data reveal that H3K27M contributes to altering expression of genes specific to
assisting in accelerating tumorigenesis, including gene-fusions and additional oncogenes.
H3K27M Increases Expression of Bivalent Gene Promoters in HGGs
The epigenetic modification H3K27me3, as previously described, is generally
associated with repressed loci, while H3K4me3 is primarily found at active promoter
sites [166, 239]. The presence of both H3K27me3 and H3K4me3 define a potential
poised or bivalent gene promotor [166]. When the H3K27M mutation is expressed, loss
of H3K27me3 leaves only H3K4me3 left to drive gene promoter activation resulting in
overall higher gene expression [160, 239]. We directly compared our list of significantly
up- and downregulated genes in the absence or presence of the H3K27M mutation from
tumor samples with a gene list generated by Suzanne Baker’s group [160] and identified
a similar proportion of potential bivalent genes when H3K27M is present (Figure 4-9A).
There was an approximately 30% increase in bivalent upregulated genes and ~28%
increase in downregulated genes in H3K27M mouse tumors compared to the total gene
list of ~12% bivalent genes (Figure 4-9A). Of the upregulated bivalent genes, Enrichr
analysis identified Gene Ontology Biological Processes to be upregulated, specifically
pathways highly associated with kinase activity, epithelial cell proliferation and Wnt
signaling (Figure 4-9B). Particular genes driving the upregulation of these pathways
include some that we identified previously and a couple novel ones: Sox9, Ntrk1, Egfr,
Ptpru, Cdk6, Wnt3 (proto-oncogene) and Cdkn1c (tumor suppressor). Closer examination
of direct comparisons of H3K27M groups with or without DSBR inhibition indicates
(p53;H3K27M)Emx1-cre gliomas had a much larger percentage of upregulated bivalent
genes compared to p53Emx1-cre control tumors, which is reflective of what the Baker lab
model uncovered. However, the greatest difference in bivalent gene promoters was
evident when we compared Brca2- and Lig4-deficient tumors (Figure 4-9C).
(Lig4;p53;H3K27M)Emx1-cre gliomas had almost 4 times the amount of upregulated
bivalent genes compared to (Brca2;p53;H3K27M)Emx1-cre. Surprisingly,
(Brca2;p53;H3K27M)Emx1-cre actually had a larger percentage of bivalent genes
considered downregulated. The difference between DSBR-deficient tumors with
H3K27M may be due to different effected neural cell populations. In the absence of the
histone mutation, H3WT gliomas, displayed a substantial increase in the proportion of
downregulated bivalent gene promoters (Figure 4-9D). Although (Brca2;p53)Emx1-cre
tumors had more overall genes marked with H3K27me3 and H3K4me3 compared to
(Lig4;p53)Emx1-cre, they both contained about the same percentage of bivalent genes
throughout. These data support that bivalency release via H3K27me3 reduction is a
highly probable mechanism for how H3K27M facilitates differential gene expression
signatures that drive gliomagenesis.
With the development and advancements in single-cell RNA-sequencing much of
the mouse brain cell network has been mapped to known gene markers [240]. Utilizing
an established dataset from Rosenberg et al. [240], we compared the mouse glioma RNA-
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Figure 4-9. H3K27M increases bivalent gene promoters in HGGs.
(A) Stacked bar graphs showing promoter status for genes up- or downregulated in
H3K27M HGGs. Gold bars represent proportion of genes with observed bivalent
promoters (H3K27me3+ H3K4me3+) from DIPG (Larson et al.) dataset that are
upregulated in the H3K27M mutant HGGs compared to H3WT. (B) Gene ontology
enrichment analysis for upregulated genes in H3K27M gliomas that display bivalent
promoters, as shown in (A) right panel, identifies effected pathways. Length of bar
indicates p-value. (C) Comparisons of all groups with up- or downregulation of bivalent
genes with the H3K27M mutation present. Total number of genes are shown on left with
greatest increase in upregulated in (Lig4;p53;H3K27M)Emx1-cre. Right graph shows the
percentage change in bivalent genes for all groups for up- or downregulated genes. (D)
Bivalent gene graphs highlighting all groups with H3WT only. Full gene counts (left) and
percentages (right). (E) Glioma grouping by average expression levels of Slit1,2,3 genes
and enrichment in gene sets corresponding to different cell populations along with
diffusion and genotype showing correlation between Slit expression, cortical cell
enrichment and diffusion (Rosenberg et al.).
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seq data to gene expression patterns to specific brain cell populations. Based on our
previous findings identifying a strong differential gene expression pattern of important
neuron development genes (Slit-Robo pathway) between Lig4- and Brca2-deficient
tumors (Figure 4-7B, C), we decided to additionally sort by Slit1/2/3 genes to examine
possible correlations with other neuron cell populations. We were not only able to
distinguish cell populations by their genotype group but also associate overall tumor
diffusion to these clusters (Figure 4-9E). A majority of mouse tumors with H3K27M
have higher gene expression in the brain regions of the cortex, olfactory bulb,
hippocampus and some migrating interneuron populations. (Lig4;p53;H3K27M)Emx1-cre
gliomas displayed the greatest gene expression in these regions with corresponding high
diffusion scores (Figure 4-9E, far left side). Increased tumor diffusion in H3K27M
groups, previously determined by histology (Figure 4-2C), correlated with these neural
gene expression patterns with similar regions of the brain effected, including dispersed
tumor cells throughout the cortices, olfactory bulbs and hippocampus. These results
suggest that the addition of the H3K27M mutation with concurrent loss of either NHEJ or
HR, severely disrupt the overall tumor genomic expression profile in the mouse cortex
and other neural cell populations, however this disruption is to a much greater extent with
NHEJ-deficiency.
H3K27M Determines Cell of Origin Susceptibility to Gliomagenesis
The importance of histone marks, H3K4me3 and/or H3K27me3, at specific stages
of neural lineage progression are known to have direct effects on neural development
[106, 166]. We examined the link between the specific cell of origin and histone marks at
critical genes that may be responsible glioma formation in our model. Principalcomponent analysis (PCA) indicates high heterogeneity presence when comparing all
mouse tumor samples to each other (Figure 4-10A). Interestingly,
(Brca2;p53;H3K27M)Emx1-cre and (Lig4;p53;H3K27M)Emx1-cre are the only two genotypes
that exhibit unique grouping from each other in the three-dimensional PCA (red and blue
circles), highlighting the significant role that H3K27M plays in differential tumor
development when combined with HR- or NHEJ-deficiency. We compared the glioma
RNA-seq data directly to methylation marks determined by Wieland Huttner’s group
[106] and found genotypes separated into unique groups of differentially expressed genes
as shown in the heatmap (Figure 4-10B). A particular subset of these genes (outlined by
red box) are universally upregulated by H3K27M, therefore have a similar genome-wide
effect on tumor development. These include but are not limited to Sox1 (embryonic
development), Egfr1 (commonly mutated cancer gene), Eya4 (DNA repair), and Car8
(cerebellar ataxia). More importantly another subgroup of genes, identified from the
methylation dataset, uniquely separated the effect that loss of HR or NHEJ had on tumors
with the H3K27M mutation (outlined by black box) (Figure 4-10B). Distinctive genes
upregulated in (Lig4;p53;H3K27M)Emx1-cre and inversely downregulated in
(Brca2;p53;H3K27M)Emx1-cre tumors include Ntn1 (axon guidance and cell migration
during development), Adra2a (nervous system development), Vgf (nerve growth factor
inducible) and interestingly Cbx7, which is part of the PRC1 complex with its primary
function being repression of Cdkn2a. Further comparison of the triple mutant tumor

67

Figure 4-10. Addition of H3K27M determines cell of origin susceptibility to
gliomagenesis between Lig4 and Brca2 loss.
(A) 3D PCA plot comparing all genotypes to each other. (Lig4;p53;H3K27M)Emx1-cre
(blue circle) and (Brca2;p53;H3K27M)Emx1-cre (red circle) highlighted to indicate greatest
difference between subgroups. All other groups show the large tumor heterogeneity of
gliomas. (B) Heatmap from the top 100 sorted genes which exhibit methylation marks
during neocortical development. Similar upregulated genes for H3K27M samples are
highlighted in red box. Differential gene expression for (Lig4;p53;H3K27M)Emx1-cre and
(Brca2;p53;H3K27M)Emx1-cre is highlighted in the black box. (C) GSEA comparing
(Lig4;p53;H3K27M)Emx1-cre and (Brca2;p53;H3K27M)Emx1-cre genes with high-CpGdensity promoters (HCP) bearing the tri-methylation mark H3K27me3 in MCV6 cells.
Genes with HCP bearing H3K4me2 and H3K27me3 in neural precursor cells (NPC). (D)
The most upregulated genes in (Lig4;p53;H3K27M)Emx1-cre or (Brca2;p53;H3K27M)Emx1cre
indicate differences related to cell type and cortical location of primary DNA damage
accumulation (γH2AX) in early development at E15.5. Lig4 – upper cortex more
differentiated/mature neurons. Brca2 – deep cortex more progenitor-like. Genes
previously identified to be bivalent in mouse NECs (Huttner et al., 2017; gold) were
compared to our dataset to identify the percentage of genes marked either H3K4me3
(red), H3K27me3 (purple), bivalent (gold), or no modifications (gray), in the defined
neural cell populations, aRG-N or Neurons, during neural lineage progression. Genes
relate directly to the bivalency at NEC for aRG-N and Neuron comparisons (LogFC>1.0
and p<0.05). (E) The total number of genes marked for each methylation state and cell
type, as shown in (D), is represented. (Lig4;p53;H3K27M)Emx1-cre have substantially more
upregulated genes in each methylation state compared to (Brca2;p53;H3K27M)Emx1-cre.
Example genes present in the three different histone marks are given below each graph.
*indicates present in both cell types.
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groups to each other by GSEA gene sets for hallmark pathways from the Molecular
Signatures Database demonstrates differences within high-CpG-density promoters (HCP)
bearing the tri-methylation mark H3K27me3 in MCV6 cells, which Mikkelsen et al.
[241] have shown to be unable to fully re-program leaving cells in a more lineage
committed differentiated state (Figure 4-10C). (Lig4;p53;H3K27M)Emx1-cre tumors
displayed strong enrichment within the MCV6 cells comparison, indicating a release of
more genes from a bivalent state with less H3K27me3 mark present. Additionally, we
used GSEA to compare our datasets to a HCP gene set bearing H3K4me2 and
H3K27me3 in neural precursor cells (NPC), which are known to have bivalent promoters
[242]. We found a similar robust enrichment in the (Lig4;p53;H3K27M)Emx1-cre group,
which is consistent with a more differentiated underlying state. Comparatively,
(Brca2;p53;H3K27M)Emx1-cre does not show enrichment in these gene sets.
As previously shown, the greatest difference in accumulation of DNA damage
early in development at E15.5 was between the location within the cortex of
(Brca2;p53;H3K27M)Emx1-cre (deep layers) and (Lig4;p53;H3K27M)Emx1-cre (upper layers)
embryos (Figure 4-10D, left panels). This highlights the potentially different progenitor
cell populations effected by Brca2- and Lig4-deficiency in these cortical layers, with
Brca2 more likely effecting early born stem/neuroepithelial cells (NECs) or apical
progenitor radial glia committed to the neurogenic lineage (aRG-N) as described by
Albert et al. [106]. While Lig4 may have more of an effect on differentiated/mature
neural cells that are post-mitotic in the upper neocortical layers. Genes that were
previously identified to be bivalent in mouse NECs [106] (gold) were compared to the
H3K27M tumor data to analyze the percentage of H3K4me3 (red), H3K27me3 (purple),
bivalent (gold), or no modifications (gray), in the defined neural cell populations (aRG-N
and Neuron) (Figure 4-10D, right graphs). A large majority of the most upregulated
genes in (Lig4;p53;H3K27M)Emx1-cre tumors retain bivalency or are turned on (H3K4me3)
as cells mature from NECs to neurons (Figure 4-10E, upper graphs). In contrast, the
genes that are upregulated in the (Brca2;p53;H3K27M)Emx1-cre group that were bivalent in
NECs were greatly reduced in total gene number in both aRG-N and neurons. However,
these same genes display a higher percentage that are turned off or silenced via
H3K27me3 alone through maturation (Figure 4-10E, lower graphs). Not surprisingly
both groups displayed reduced gene promoters with the H3K27me3 mark, validating the
effect of the H3K27M mutation. Affected genes linked to tumorigenesis and
neurodevelopment include Pdgfβ, Cdkn2a, Sox9, and Syn2 (Synapsin II) in the
(Lig4;p53;H3K27M)Emx1-cre group and Runx1 (also known as oncogene AML1) and Alox5
(regulator of leukemia stem cells) in the (Brca2;p53;H3K27M)Emx1-cre tumors.
Interestingly Cdkn2a was the only gene positive for H3K4me3 through all of the
developing cell types in downregulation of (Lig4;p53;H3K27M)Emx1-cre tumors, indicating
its active gene expression and underlining its importance in gliomagenesis for this
particular group. Collectively, these data show in the mouse neocortex the presence of the
H3K27M mutation and Lig4-deficiency, results in DNA damage that preferentially
effects a more mature neural cell population and genes in these cells are critical for
proper neural development and tumorigenesis. Nevertheless, Brca2-deficiency with
H3K27M cause DNA damage primarily in proliferating and immature progenitors,
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therefore reprogramming and altering the pluripotency potential by decreasing bivalency
within these critical early born progenitor cells that eventually transform into tumor cells.
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CHAPTER 5.

DISCUSSION

This dissertation analyzes and summarizes the role of DSBR, HR (Brca2deficiency) or NHEJ (Lig4-deficiency), during neurogenesis and high-grade glioma
development. Mutations in DNA repair genes have been linked to various
neurodegenerative diseases and cancers, including brain tumors [66, 243-245]. These
diseases underly the importance that DNA repair pathways play in maintaining genome
stability during early development of the nervous system. However, much is still
unknown regarding the pathobiology of defective DNA repair including DSBR,
particularly in the context of specific neural cell types and regions of the brain. Therefore,
understanding how gene alterations in early brain development result in tumorigenesis
will help us answer these questions. Throughout this dissertation I have presented my
work investigating how the loss of DSBR, HR (Brca2) or NHEJ (Lig4), effects
neurogenesis and eventually leads to gliomagenesis in the mouse cortex. Additionally, I
examined a histone H3 (H3K27M) mutation that influences high-grade gliomagenesis, to
identify potential cooperation between this oncohistone and heightened genome
instability.
DSBR-Deficiency in Cortical Progenitor Cells
Analysis of the loss of DSBR, HR and NHEJ via conditional Brca2 and Lig4 loss,
respectively, using Emx1-cre recombinase to target gene inactivation to the neocortex
revealed that Brca2Emx1-cre and Lig4Emx1-cre resulted in DNA damage accumulation that
correlates with apoptosis in specific layers of the neocortex (Figure 3-1). Similarly,
DSBR mutant mice with additional p53 inhibition revealed large amounts of DNA
damage present in the neocortex, however more in the form of DSBs identified by
γH2AX-foci. (Brca2;p53)Emx1-cre embryos at E12.5 had more damage accumulation, but
just three days later in development at E15.5 (Lig4;p53)Emx1-cre embryos amassed
significantly more DNA damage, especially in the upper post-mitotic cortical layers
(Figure 3-6). Contrastingly, (Brca2;p53)Emx1-cre cortices primarily retained damage to the
deep proliferative layers, supporting the differential roles HR and NHEJ play in DSBR in
specific cell populations of the developing cortex. The difference in DNA damage
present at E12.5 between Brca2- and Lig4-deficient mice highlights the importance and
efficiency of HR in early proliferative progenitors. In the progenitors where HR is
inhibited, the cells rely on NHEJ, which as a consequence of its error-prone nature
occasionally results in improperly repaired DNA. When NHEJ is inhibited at E12.5, we
see less DNA damage accumulation compared to HR-deficiency, albeit still at a high
level compared to controls. This is because HR cannot completely compensate for the
loss of NHEJ, which is more functional throughout the cell cycle. Brca2Emx1-cre primarily
affected the “deep” VZ and SVZ cortical layers, while Lig4Emx1-cre largely created cell
death in the “upper” CP and MZ layers. This clear preferential difference in affected
cortical cell layers between Brca2- and Lig4-deficient mice was frequently identified
throughout my studies, supporting the importance of HR in replicating cortical progenitor
cells and NHEJ in post-mitotic neurons.
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A specific subset of the earliest born stem and progenitor cells reside at the apical
surface of the neocortical VZ, referred to as apical stem or progenitors (APs). APs
undergoing mitosis were identified using the phospho-histone H3 mitotic marker, which
allowed us to confirm activation of the G2/M checkpoint by DNA damage in these cells.
Interestingly, at E12.5 (Lig4;p53)Emx1-cre mice displayed significant induction of G2/M in
APs, while (Brca2;p53)Emx1-cre indicated no change in mitotic positive APs compared to
controls. However, at E15.5 both DSBR mutants activated the G2/M checkpoint to
similar extents. These results validated that DNA damage induced the G2/M cell cycle
checkpoint in the critically important AP cell population of the cortex. It’s been shown
that cells in which p53 is inhibited, like in our model, lose the G1/S checkpoint and
therefore cannot arrest at the G1/S transition [204], although they can maintain a G2/M
arrest. For this reason, we did not see any significant activation of the G1/S checkpoint in
any of the mice through BrdU analysis. Though this is by no means a robust study on cell
cycle dynamics it is intriguing to speculate on the differential consequences that loss of
HR and NHEJ have on the cell cycle of cortical progenitors in early development. From
E10 to E12, rapidly proliferating APs undergo symmetric divisions and have about 3-4
times longer S-phases than after the cells differentiate [24]. However, after E13,
differentiated cells have shorter S-phases and longer G1 phases [25]. We know that
genome maintenance is critical for early-born APs and the increased S-phase length
allows for cells to invest more time into quality control [21, 24]. This is a stage in which
BRCA2 and HR function is essential for maintaining DNA integrity during replication.
Because we observed HR-deficient embryos having relatively higher amounts of DNA
damage accumulation at E12.5, than NHEJ, this suggests BRCA2 and HR may have
increased importance in early progenitors because of the longer S-phase. Additionally,
previous data from our lab has shown the possibility of different damage threshold
limitations in the earlier born progenitors. We showed that cortical progenitors have
increased sensitivity to DNA damage inducing agents at E11 compared to E14 [75].
Thus, the loss of HR during the longer and more critical genome surveillance period, in
early-born cortical progenitors, compromises DNA fidelity by the accumulation of stalled
replication forks and DSBs which allow for increased gene alterations and mutational
burden.
The complex events associated with cell cycle regulation and DNA damage
threshold may offer an explanation to why neither mice using Nestin-cre,
(Brca2;p53)Nestin-cre or (Lig4;p53)Nestin-cre, develop HGGs but rather form
medulloblastomas [49, 58, 169]. Perhaps this is also due to differences in transcriptional
programing of cortical progenitors at the stages of Emx1- and Nestin-cre expression.
Although the activation of either cre is only separated by about one embryonic day, with
Emx1-cre earlier at ~E9.5, this is enough time for progenitor cells in the dorsal
telencephalon to undergo significant expansion and cell fate commitment to
corticogenesis [74]. In a similar manner, Nestin-cre targets progenitors that more
committed to other cell fates like cerebellum development, including a large population
of granule neurons in the hindbrain, which by probability increase the likelihood of
medulloblastoma formation. It’s also possible that the Nestin-cre mouse used was
insufficient for recombination in early neural progenitors, as one group discovered [61].
This is not to say that Emx1-cre expression does not have off target effects. Aside from
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mice succumbing to HGGs, many are prematurely euthanized for various reasons
including clavicle masses or submandibular cervical lymph node enlargements, indicating
possible Emx1-cre nonspecific effects [246, 247]. Consequently, it appears that as
progenitors progress through lineage specificity, the cells intrinsic properties may change
concerning their susceptibility to DNA damage, cell cycle dynamics and principal
replication differences. A previous study by our lab supports this concept as it discovered
that TopBP1, a protein linked to DNA replication, prevents replication-associated DNA
strand breaks in early cortical progenitors in an Emx1-cre mouse model but not in Nestincre mice [75]. Studies like these, using genetically engineered mouse models allows us to
speculate the differences in regulation of DDR as progenitors mature. Therefore, we
propose BRCA2 and LIG4 contribute uniquely to genome stability in early-born and
later-born progenitor cell populations.
HR- and NHEJ-Deficient Tumor Gene Expression Patterns
Inactivation of p53 in DSBR-deficient mice results in a drastic decrease in overall
tumor-free survival, by the development of high-grade gliomas (Figure 3-3). Loss of p53
function was necessary for gliomagenesis in these mice, much like in many pediatric
cases [81, 82, 154, 183]. The data presented in my dissertation show the first analysis of a
mouse model with early endogenous disruption of DSBR restricted to the cortex
generating HGGs that resemble the pediatric disease.
Transcriptome analysis from RNA-sequencing data we collected on representative
mouse HGG samples identified distinctive gene expression profiles associated with loss
of HR or NHEJ. Predictably, many compensatory DNA repair genes were found to be
significantly upregulated in (Brca2;p53)Emx1-cre gliomas, including Tdp1, Prkdc, Alkbhd2,
Brcc3 and Atrx (Figure 3-4), while (Lig4;p53)Emx1-cre tumors had a significant
upregulation of kinases, like CCND3 and MAP3K1, which are specific to cancer
development and tumor progression [103, 134, 193]. The differential gene expression
patterns between Brca2- and Lig4-deficient gliomas highlight the importance of HR for
DNA repair fidelity in replicating tumor cells. Without proper HR, cells must rely on
other DNA damage repair pathways, like NHEJ and SSBR, for repair in order to
proliferate and survive. In the case of Lig4-inhibition the cells have intact HR in early
replicating cells, therefore errors in DNA repair resulting in mutations favoring
tumorigenesis probably occur later in embryonic development. Genomic analysis of
RNA-seq data identified recurrent chromosomal rearrangements, or potential genefusions, and amplifications in DSBR-deficient mouse gliomas (Figure 3-5) that are
reflective of human brain tumors [90, 199]. The most commonly found gene-fusions
involved Pdgfrα, Braf and Met, and were more prevalent in (Brca2;p53)Emx1-cre gliomas.
Whole exome sequencing to identify the average number of somatic mutations revealed
that (Brca2;p53)Emx1-cre tumors had almost three times as many mutations than
(Lig4;p53)Emx1-cre tumors. This data suggests that loss of HR results in greater
accumulation of mutations, some of which were specific gene-fusion alterations that are
known to cause HGGs. This is in all likelihood due to the higher frequency of errors in
DNA repair through NHEJ culminating in more mutations. Earlier born progenitors
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especially require effective DSBR because any errors or resulting mutations have the
potential to pass onto progeny cells increasing the possibility for devastating
consequences, i.e. tumorigenesis.
The difference at E15.5 in cortical DNA damage is primarily due to the expansion
of progenitor cells undergoing differentiation and maturation into post-mitotic neurons.
As previously stated, NHEJ is the main form of DSBR once progenitors exit the cell
cycle, because HR is only functional in replicating cells. Loss of NHEJ in the maturing
neurons is detrimental because these cells must rely on a less efficient form of DSBR, altNHEJ, and other types of repair like SSBR, BER and NER [45, 46]. Our lab has
previously shown that Lig4Nes-cre mice accumulate γH2AX throughout the brain with age
[12], indicating the other repair pathways are insufficient for repair. Therefore, in this
model we see that Lig4-deficiency and NHEJ impairment results in a large accumulation
of DNA damage in the upper cortical layers consisting of more mature, non-cycling cells
(Figure 3-6). Although we expected more damage would result in more mutations
leading to increased tumorigenesis, the difference in total amount and location of DNA
damage surprisingly did not affect tumor latency or overall survival between either
DSBR-deficient mouse models. Our findings underline the general importance of both
DSBR pathways in providing genome stability to specific cortical cell populations during
early development to prevent gliomagenesis.
H3K27M Increases Genome Instability and Accelerates Gliomagenesis
Histone H3 mutations are critical events in pediatric high-grade gliomagenesis
[80-82, 90, 248]. The most common histone mutations found in these gliomas are
H3K27M and H3G34R/V with both affecting distinct brain regions and developing at
particular time periods. The discovery that DSBR-deficient mice with coincident p53
inactivation develop HGGs, lead us to investigate the effect of H3K27M mutation in
DSBR-deficient background. We hypothesized that the histone mutation may affect
chromatin conformation leading to increased DNA damage susceptibility as part of the
mechanism leading to glioma formation. My studies provide evidence for a novel role of
H3K27M in gliomagenesis, providing a second perspective on the mechanism by which
loss of H3K27me3, via H3K27M mutation, may contribute to cancer development. In
testing this, we found that expression of the H3K27M mutation in the neocortex causes
cortical progenitors to impede efficient DSBR and alter genome homeostasis. This was
shown by genome instability in H3K27M progenitor cells and association with DSBR
(HR/NHEJ) deficiency and increased tumorigenesis (Figures 4-2 and 4-3). The observed
increased frequency of DNA damage with or without additional DSBR mutations suggest
that the genome of H3K27M progenitor cells is more susceptible to damage and poised
for gene alterations, with the consistent loss of H3K27me3, from the earliest periods of
development through gliomagenesis (Figure 4-1).
Early cortical development is associated with replication stress which has shown
to result in preferential sensitivity to common fragile sites [249, 250]. Our results are
consistent with previous findings that indicate H3K27M mutations are not sufficient on
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their own to induce tumorigenesis [156, 160] but rather put cortical progenitor cells in a
poised pre-cancerous state characterized by bivalent gene promoter expression,
replication stress and spontaneous DNA damage, where deficient DSBR promotes
genome instability (Figure 4-9). Progenitor cells harboring gene aberrations are likely to
undergo cell death unless tumor suppressors (i.e. p53) are inactivated or oncogenes are
activated [147, 156, 160, 164]; however, widespread loss of H3K27me3 and/or
H3K27M-induced replication stress could largely enhance accessibility to malignancy of
the pre-cancerous progenitors and help them to avoid apoptosis, as shown in
(p53;H3K27M)Emx1-cre mice having substantially high levels of DNA damage (Figure
4-3). p53 inactivation in DSBR-deficient mice display significantly decreased apoptosis;
similarly, H3K27MEmx1-cre mice alone accrue DNA damage but do not develop HGGs and
require p53 inhibition to drive tumorigenesis. Although, these results were not that
unexpected, as H3K27M mutations are found in over 70% of DIPG patients [81, 82],
exogenous expression of H3K27M alone has been shown to be insufficient to induce
neoplastic transformation of neural progenitor cells [155, 156]. The combination of
additional key mutations in oncogenes (PDGFRα) and/or tumor suppressors (p53) are
almost always required to promote tumorigenesis [81, 82, 155, 156, 160]. Our model uses
an endogenous targeted gene expression method to activate the H3K27M mutation and
inactivate DSBR genes (Brca2/Lig4) and p53 at one of the earliest known viable time
points in the mouse brain. One limitation of this model is its specificity to the cortex and
not the pons/midbrain where H3K27M related DIPGs are traditionally identified [160],
nevertheless this model still produces HGGs that resemble the pediatric disease. This
study, along with others, support a consistent role that H3K27M induces tumor formation
[155-157, 160, 162].
One key question that still remains unanswered is the effect of the related histone
H3 mutation, H3G34R/V. Since H3G34R/V mutations are typically found in the cortex
of older pHGG patients and some aHGGs, it would seem that a mouse model driving
gene expression only to the cortex would be the perfect candidate to study this specific
oncohistone. In an identical manner to the H3K27M model, the H3G34R conditional
knock-in mutation was created separately by Suzanne Baker’s group. Interestingly, in
crossing H3G34REmx1-cre with p53-, Brca2-, Lig4-conditional gene ablation we were
unable to generate consistent HGGs that had latency differences to the (Brca2;p53)Emx1-cre
or (Lig4;p53)Emx1-cre mice. Additionally, the incidence of (p53;H3G34R)Emx1-cre tumors
were comparable to p53Emx1-cre mice. Suggesting that H3G34R was not contributing to
tumorigenesis in any substantial manner. The inability of H3G34R to influence
tumorigenesis in physiological settings, like mouse models, is consistent with what other
groups have observed [154]. The explanation behind this is speculative and could be due
to multiple reasons, including the specific targeted cell population and/or the timing of
mutational gene activation. Although this question remains unanswered, it leaves much
opportunity for further investigations.
We identified global reduction of H3K27me3 in cortical embryonic tissue at
E12.5 and E15.5 in the H3K27M mutant mice (Figure 4-1), which is a well reported
epigenetic modification attributed to this mutation [147, 163, 205]. To our knowledge,
this is the earliest evidence showing the immediate effects of endogenous expression of
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this histone mutation in a mouse model. Additionally, we found a modest increase of K27
acetylation within specific upper and deep neocortical layers of the H3K27M mice,
suggesting an increase in gene activation. Histological analysis revealed a similar loss of
H3K27me3 expression in all H3K27M mutant tumors, in combination with or without
Brca2-, Lig4- and p53-inactivation. These results suggest the effects of H3K27M on the
epigenome are present at the earliest stages of development and carry all the way through
development into gliomagenesis. Therefore, activation of the H3K27M mutation via
Emx1-cre recapitulates the consequence of this oncohistone as seen in other scenarios,
independent of DSBR-deficiency.
H3K27M and DSBR-Deficiency Increase DNA Damage and Tumorigenesis
The impact of the H3K27M mutation towards tumorigenesis in either
(Brca2;p53)Emx1-cre or (Lig4;p53)Emx1-cre was assessed by the generation of
(Brca2;p53;H3K27M)Emx1-cre and (Lig4;p53;H3K27M)Emx1-cre mice. We found a
pronounced acceleration of tumor occurrence with a decrease in survival by about 4
months in the mice with the H3K27M mutation (Figure 4-2). Interestingly,
(Brca2;p53;H3K27M)Emx1-cre mice succumbed to HGGs on average about two weeks
earlier than (Lig4;p53;H3K27M)Emx1-cre mutants, suggesting a differential link between
H3K27M with HR or NHEJ. Comparatively, (p53;H3K27M)Emx1-cre mice develop HGGs
more quickly than the DSBR-deficient mutants alone but not as rapidly or as frequent as
the triple mutants. Furthermore, the presence of the H3K27M mutation increased tumor
diffusion, supporting its known role in driving diffuse high-grade gliomagenesis [81, 82,
155, 160]. Phenotypically, mice carrying H3K27M were significantly smaller in overall
size compared to littermate controls until at least weaning age at P21, indicating a defect
in early growth development. In addition to initial delay in growth, these mice
demonstrated extreme hyperactive behavior throughout their lifespan. One possible
explanation for hyperactivity could be due to the loss of the repressive mark, H3K27me3
and consequently resulting in an increase of overall gene expression via activating marks
like H3K27acylation and H3K4me3, causing their brains to almost go “haywire.”
Performing in vivo electrophysiology experiments could uncover a deeper understanding
of the neuronal firing mechanisms that may also be causing this hyperactive behavior.
One recent study linked commonly mutated PI3 kinase variants in glioblastomas to
initiating brain hyperactivity during gliomagenesis [251].
Embryonic analysis identified significantly increased levels of DNA damage in
mice harboring the H3K27M mutation (Figure 4-3), with selective differences in damage
levels at E12.5 and E15.5 between the DSBR-deficient mutants, similar to what was
found in mice without the histone mutation. At both embryonic timepoints analyzed
(Brca2;p53;H3K27M)Emx1-cre mice had significant increases in γH2AX-foci in the deep
cortical layers compared to all other genotypes. Comparatively, (Lig4;p53;H3K27M)Emx1cre
showed no amplification in damage with H3K27M in the lower highly proliferative
cortical cell populations, reiterating the importance of functional HR repair in early-born
cortical progenitors. Remarkably, at E12.5 the levels of damage in the
(p53;H3K27M)Emx1-cre mouse alone were significantly higher than an NHEJ-deficient
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mouse, (Lig4;p53)Emx1-cre, and as equally high as both (Lig4;p53;H3K27M)Emx1-cre and
(Brca2;p53)Emx1-cre mice. Furthermore, at E15.5 we found the addition of the H3K27M
mutation with Lig4-deficiency intensified DNA damage only in the upper differentiated
(post-mitotic) cortical cell layers, which was nearly double the amount as the deep layers.
Interestingly, when combining the total amount of DNA damage, both deep and upper
layers combined, all mice with H3K27M had more γH2AX-foci than their H3WT
counterparts at E15.5. Taken together this implies that the H3K27M mutation is acting in
a non-specific manner intensifying genome instability, which contributes to accelerating
tumorigenesis, particularly in the presence of DSBR-deficiency.
The Role of H3K27M in Genome Instability
One of the most interesting findings from the embryonic DNA damage analysis
was that not only did (p53;H3K27M)Emx1-cre mice have γH2AX foci but at such intense
levels. At E12.5 the levels of damage were significantly higher than an NHEJ-deficient
mouse, (Lig4;p53)Emx1-cre, and as equally high as both (Lig4;p53;H3K27M)Emx1-cre and
(Brca2;p53)Emx1-cre mice. However, at E15.5, (p53;H3K27M)Emx1-cre mice only had more
damage than their counterparts, p53Emx1-cre, which was mostly confined to the deep
proliferative cells. This discovery was somewhat of a surprise because it suggested for
the first time, in a physiological setting, that H3K27M is associated with genome
instability. We can only speculate on how mechanistically this could be possible, but one
explanation is that the histone mutation may impair core subunits of the PRC2 complex,
like EZH2, resulting in a stable chromatin conformational change [151]. Recent studies
show this could be through inhibition of EZH2 automethylation, a process where EZH2
increases its histone methyltransferase activity to attain high enough levels of
H3K27me3, thereby creating a conformational change that is normally required for EZH2
activity [252-254]. This change conceivably results in a more open chromatin structure
which has increased susceptibility to DNA damage [207-209]. Because histone mutations
occur on the N-terminal tails, that are unstructured regions undergoing extensive posttranslational modifications, these alterations consequently recruit effector proteins that
directly control transcriptionally active (open) or silent (closed) chromatin states [248].
Additional evidence through ATAC-seq in other H3K27M models have shown more
open chromatin states directly due to the histone mutation [150], which in theory allows
for more susceptibility to DNA damage. A simplistic interpretation of this is that a more
open chromatin conformation state prolongs DNA exposure to damage inducing
replicative stress, while a more closed, heterochromatin state, offers more protection from
these stresses [255, 256]. Interestingly, euchromatin is more sensitive to DNA damage
caused by chemical agents, like cisplatin [255]. This opens the possibilities of exploring
the use of different DNA damage inducing agents to treat pHGG patients, especially with
histone mutations. Although, this is an extremely complex subject with many obstacles to
overcome, including the blood brain barrier, it is a focus being studied by others [55, 94,
257].
Further evidence suggests, that acetylation and/or a decrease in methylation levels
promote more open or “relaxed” chromatin structure [209, 258, 259], which aligns with

78

the epigenetic modifications that H3K27M produces. One recent study found that in
human dermal fibroblasts H3K27 methylation facilitates NHEJ through FANCD2 [260].
This study showed that transduced H3.1 K27M mutant cells had robust 53BP1 foci (DNA
damage marker), increased genomic alterations and increased p53-dependent apoptosis.
Likewise, Janet Partridge’s lab showed in a fission yeast model, cells expressing the
histone H3G34R mutation caused a defect in response to S-phase induced DNA damage
resulting in defective HR and genome instability [261]. Evidence like this, suggests that
H3K27M could be acting in a more direct manner towards DDR by inhibiting HR. Our
data supports that HR is the more probable targeted repair pathway as the levels of
damage identified in (p53;H3K27M)Emx1-cre embryos were highest at E12.5 when HR
fidelity is most important. In addition, at E15.5 the vast majority of damage resulting
from these mice were in the deeper proliferative cortical layers similar to the Brca2deficient embryos. Although this does not offer a complete explanation into the
mechanisms of H3K27M associated DNA damage, it does provide a probable novel role
that H3K27M plays in tumorigenesis. Additionally, this presents some insight for
additional research studies to further explore the relationship not only between histone
mutations and DNA damage repair but also gliomagenesis and possible therapeutic
targets.
The increased levels of DNA damage from the H3K27M mutation that we
observed, stemmed the hypothesis that there would be an increase of checkpoint
activation in apical cortical progenitors, similar to findings from mice without H3K27M.
At E12.5 we found that H3K27M associated DNA damage induced G2/M checkpoint in
both (Brca2;p53;H3K27M)Emx1-cre and (p53;H3K27M)Emx1-cre (Figure 4-4).
(Lig4;p53;H3K27M)Emx1-cre and (Lig4;p53)Emx1-cre mice had similar amounts of mitotic
positive cells so this effect could be directly associated to NHEJ-deficiency. Additionally,
at E15.5 we found similar levels of G2/M checkpoint induction in all genotypes in the
apical cortical progenitor cells, with a slight increase in (Brca2;p53;H3K27M)Emx1-cre
mice. Due to the large cortical expansion at E15.5 we were able to additionally identify a
small population of basal progenitors undergoing mitosis using pH3 and Tbr2 markers.
Studies have shown that directly reducing H3K27me3 on the Eomes locus, a key basal
progenitor regulator of Tbr2 in NSCs of mice, not only reduces the number of Tbr2
positive cells in the cortex but also directly decreases the amount of basal progenitors
undergoing mitosis [106, 210, 211]. Granted the number of mitotic positive cells in this
particular region are far and few between, we still found a reduction in all cohorts
containing the H3K27M mutation. This provides evidence that the increase in H3K27Massociated DNA damage induces the G2/M cell cycle checkpoint in attempt to repair
broken DNA strands, specifically in early-born apical cortical progenitor cells.
H3K27M Drives Unique Gene Expressions Between HR- and NHEJ-Deficiency
Gene expression analysis, via RNA-seq, identified expression changes that were
not only unique to H3K27M tumors but further differentiated the H3K27M-DSBRdeficient mouse tumors from each other. Unsupervised hierarchical clustering and
principle component analysis revealed that all H3K27M tumors group together more than
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H3WT tumors, suggesting that H3K27M may be affecting similar genes which are
actually reducing tumor heterogeneity (Figure 4-5). Although H3K27M pHGGs have
traditionally been defined as highly heterogeneous [125, 184, 262], recent studies
analyzing large amounts of pediatric glioma samples have identified an assortment of
additional commonly mutated genes within these tumors [80, 90, 120, 141]. Accordingly,
we identified many gene alterations in H3K27M mouse gliomas that were similar to the
mutations found in pHGGs, such as: Egfr, Fgfr2, Lin28b and Pten (Figure 4-8). Lin28b
and Plag1 are both oncogenes genes important for regulating NPC proliferation and
differentiation [263-266] and we, along with others, identified both as upregulated in
H3K27M mouse gliomas [156, 160]. Interestingly, (Lig4;p53;H3K27M)Emx1-cre tumors
had downregulation of the tumor suppressor Cdkn2a, which has been associated with
residual PRC2 activity and dysregulation in many H3K27M mouse models and DIPG cell
lines [90, 155, 157, 160, 205, 267].
One explanation offered for dysregulated gene expression patterns in H3K27M
tumors is that the loss of H3K27me3-repression is overpowered by selective recruitment
of residual PRC1/2 activity on gene loci resulting in downregulation [160]. This
argument is strengthened when analyzing the most downregulated genes in the H3K27M
groups were homeodomain transcription factors such as: homeobox genes Hoxa gene
cluster (Hoxa2-7 and 10) were identified. Hoxa genes are usually tightly regulated by
transcriptional repressors for proper embryonic development (neurogenesis and
differentiation) [212] and these genes by contrast were upregulated in H3WT tumors
(Figure 4-5). Kristian Helin’s group also identified reduced expression of Hoxa genes
(Hoxa3-6) in H3K27M NSCs. They speculated that based on the identity of Hoxa genes,
H3K27M may lead to a selection of a specific cell type during the transformation process
wherein these cells are silenced by polycomb-group (PcG) proteins [157]. Another recent
study showed that reduced H3K27me3 altered Hox gene expression resulting in neural
tube defects [268]. This suggests that H3K27M may preferentially downregulate Hoxa
genes through the loss of H3K27me3 to more effectively control transcription and
decrease cell differentiation. Furthermore, PRC1 components, which we also identified as
upregulated in H3K27M, have been linked to stable repression of Hoxa genes [216].
Altogether this data suggests that a key mechanism of H3K27M may be to strengthen a
transcriptional pattern specific to the cell of origin during the early stages of oncogenic
transformation [156, 157].
Comparison of gene expression to other H3K27M mouse models and patient
samples [82, 155, 157, 160] revealed additional genes potentially contributing to
H3K27M tumorigenesis and specifically identifies a subset of genes that are directly
upregulated in many H3K27M expressing samples. These genes include Vcam1, Agt,
Peg3/10, Pbx3, Slit2, Ndn, Bmi1, Id4, Eya1/2/4, Cdkn1c and Plag1 (Figure 4-5). Many
of the genes have been implicated in assisting in tumorigenesis through various
mechanisms and therefore could potentially be utilized as future therapeutic targets for
glioma treatment [132, 219-222, 227]. In particular, Bmi1, is an optimal target for therapy
in these glioma models because its role has been well characterized in regulating
H3K27me3 on chromatin and it has been shown to be recruited to DNA strand breaks
contributing to H2A-ubiquitination and DNA repair [227, 269]. Gene targets such as
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Bmi1, could be confirmed through protein and/or IHC markers or more thoroughly
through chromatin immunoprecipitation [226]. Classification in gliomas would support
preliminary studies using therapeutics to be tested in primary in vitro cultures. Early
initial work from our lab has proven success in establishing primary cultures from mouse
gliomas, which can be used for initial drug treatment trials. This could further lead to
studies conducting the application of novel individual or previously established
combinatorial drug treatments postnatally. DNA damage inducing drugs or treatments
such as cisplatin, bleomycin, camptothecin, PARP-inhibitors and/or irradiation are
commonly used to treat different forms of cancer [50, 144, 192, 225]. Therefore, these
treatments and others could be optimized to target gliomas with DNA repair defects
and/or histone mutations [144]. Some of the challenges of designing future therapeutic
studies will be determining the optimal dosage to cross the blood brain barrier and the
proper timed regimen as it is still unknown of when gliomas in these models would be
best suited for treatment. Because of the rapid expansion of novel drugs targeting highly
specific proteins, it is not inconceivable to imagine one day treatments targeting both
DNA damage repair pathways and histone mutations could be utilized in pediatric brain
tumor patients.
H3K27M Alters the Cell of Origin
In alignment with the known roles PRC1 and PRC2 play in modulating H3K27M
and H3K27me3, we found many upregulated genes from each complex where enriched in
H3K27M gliomas, such as PRC1 (Ring1b and Bmi1) and PRC2 (Ezh2, Suz12, and
Jarid2) (Figure 4-5). Because we identified a profound loss of H3K27me3
embryonically in the histone mutants alone, we propose the upregulation of the PRC1/2
genes are directly linked to H3K27M and not a universal effect of increased tumor
proliferation. In connection to their roles in facilitating H3K27me3, Bmi1 and Ezh2, have
also been closely linked to DSBR through regulation of HR, G2/M cell cycle arrest and
p21 expression, which is involved in p53-dependent DNA damage checkpoint [269, 270].
Filbin et al. showed that PRC2 dysfunction in H3K27M gliomas contained
overexpression of Bmi1 which drives a more OPC-like tumor population [120]. OPCs
have been suggested to be the cell of origin for some types of pHGGs [120, 167, 168,
271]. Our IHC and gene expression analysis indicated OPCs or oligodendrocytes as
convincing candidates for initiating cell populations in H3K27M tumors especially with
Brca2-deficiency (Figure 4-2). The cell of origin for gliomas has been widely studied but
still many questions remain surrounding their identification in various brain tumors [91,
97, 98]. A better understanding of the potential cell type that is susceptible to specific
oncogenic mutations will allow us to better develop more effective targeted treatment
strategies.
Using IHC and various methods of glioma gene expression comparisons we
attempted to assign potential neural and glial cell populations as originating cells for the
HGGs. We found that (Lig4;p53)Emx1-cre tumors displayed more oligodendrocytic
signatures in direct comparison to (Brca2;p53)Emx1-cre by gene expression analysis and
Olig2 immunostaining. However, the addition of H3K27M expression with Lig4- or
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Brca2-inhibition resulted in increased expression of both astrocytic and astroglial
signatures, suggesting a possible shift in cellular origin due to the histone mutation.
Histological analysis confirmed a significant increase in astrocyte populations in
(Brca2;p53;H3K27M)Emx1-cre and (Lig4;p53;H3K27M)Emx1-cre gliomas with robust GFAP
expression. (Brca2;p53;H3K27M)Emx1-cre also displayed an increase in oligodendrocytes
throughout the forebrain, indicating a highly mixed glial cell population. Embryonic
analysis identified the loss of HR directly impacts earlier precursor cell populations in the
lower cortical layers, these are among the most highly proliferative and earliest forming
progenitor cells that have potential to give rise to neurons, astrocytes and OPCs, which
can differentiate into oligodendrocytes. Conversely, NHEJ functions as the primary repair
pathway in more differentiated and mature, lineage committed cell populations, such as
astrocytes. Although preliminary, this data does provide insight into how the
susceptibility of cortical progenitor cells, to oncogenic and tumor suppressor mutations,
might contribute to gliomagenesis.
H3K27M and NHEJ-Deficiency Effect Neural Development Genes
All Lig4-deficient gliomas, with or without H3K27M, have an upregulation of
genes involved in neural processes including neuron projection guidance, axon
development, as well as cell fate commitment (Figure 4-7). These genes have slightly
higher expression in the (Lig4;p53;H3K27M)Emx1-cre group, which also have the greatest
tumor diffusion among all analyzed mouse gliomas. The above neural processes are
common among mature neurons in early cortical development where NHEJ (LIG4) is
important for genome stability [21]. We found these processes were upregulated in
glioma tissue samples, suggesting that dysregulation is carried through development and
tumor cells are using these mechanisms in an advantageous manner. One interesting
subset of genes within the upregulated neural processes were the Slit-Robo gene family
members, including Slit1/2 and Robo1/2. Post-translational modifications, like H3K4me3,
H3K27me3 and H3K27 acetylation have been linked to regulation of Slit-Robo genes in
terms cell migration and cancer invasion in the central nervous system [228]. Slit-Robo
genes have also been identified as critical factors in neurogenesis and gliomagenesis
[228, 272-274]. Additionally, a subgroup of protein tyrosine phosphatase (Ptp) genes
Ptpru, Ptprn, and Ptpn5 were selectively upregulated in (Lig4;p53;H3K27M)Emx1-cre
gliomas. PTPs are reported to be involved in regulation of a variety of cellular processes
including cell growth, differentiation, mitotic cycle, oncogenic transformation, and
glioma development [129, 235, 236]. Other groups have recently identified H3K27M
DIPG patient tumors to contain upregulation of similar pathways involving neuron
development, including axon guidance and genes associated with oligodendroglial
differentiation [167]. Altogether this data suggests that Lig4-deficiency and even more so
with H3K27M expression, are selectively overexpressing genes that further promote
tumor cell migration and diffusion.
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H3K27M and Bivalent Gene Promoters
The discovery of bivalent gene promoters [166] and recent evidence supporting
H3K27M drives bivalent gene activation in similar mouse models [160, 162] sparked our
interest to explore these signature patterns in the gliomas. We directly compared
significantly up- and downregulated genes in the absence or presence of the H3K27M
mutation from mouse glioma samples with a gene list generated by Suzanne Baker’s
group that defined histone marks on gene promoters from H3WT DIPGs [160].
Surprisingly, this revealed a similar percentage of upregulated bivalent genes in both
H3K27M and H3WT gliomas, although H3K27M tumors had almost double the total
number of bivalent genes (Figure 4-9). We were initially expecting to see a large
increase in the proportion of upregulated genes in H3K27M gliomas compared to H3WT
groups that were marked as bivalent promoters, which is what we found in
(p53;H3K27M)Emx1-cre gliomas compared to p53Emx1-cre control tumors and this is
reflective of what the Baker lab discovered. However, there was a striking difference in
bivalent gene promoters when we compared Brca2- and Lig4-deficient tumors with or
without H3K27M expression. The (Lig4;p53;H3K27M)Emx1-cre tumors had almost 4 times
the amount of upregulated bivalent genes compared to (Brca2;p53;H3K27M)Emx1-cre (492
vs 136 genes, respectively). Remarkably, (Brca2;p53;H3K27M)Emx1-cre had a larger
percentage (46%) of bivalent genes that were downregulated, which potentially stems
from the original cortical cell populations that Brca2- and Lig4-deficiency most likely
effect. When we compared H3WT tumors we found relatively no difference in
percentage of bivalent gene promoters between DSBR-deficient gliomas, supporting the
role of H3K27M-mediated release of bivalent promoters. Even though (Brca2;p53)Emx1-cre
gliomas had slightly more overall downregulated bivalent genes than (Lig4;p53)Emx1-cre,
they both had about the same percentage of bivalent genes throughout. These data
support that bivalency release via H3K27me3 reduction at promoter regions is a highly
probable mechanism for how H3K27M facilitates differential gene expression signatures
which are important for gliomagenesis.
Although the research on bivalent gene promoters and their interaction with
H3K27M is relatively new, other groups have attempted to study this in cultured settings,
including NPCs and NSCs. One study found that overexpression of H3K27M in human
NPCs resulted in bivalency remaining at promoters and H3K27me3 only being reduced
in the gene bodies [156]. While another group showed that overexpressing H3K27M and
H3WT in mouse NSCs resulted in a large amount of differentially expressed genes that
were not linked to H3K27me3 in H3WT NSCs, indicating an indirect effect of H3K27M
[157]. Our data of bivalent gene promoter analysis aligned more with the results
produced from Baker lab models, which was likely due to the use of the same H3K27M
conditional mouse that regulates the histone mutation at relevant physiological levels
from its endogenous promoter. Although, arguably our models target different mouse
neural cell populations during gene activation through the use of distinct crerecombinases and result in locationally diverse gliomas. These differences further support
the probable direct impact H3K27M expression has on poised bivalent gene promoters in
a physiological setting.
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H3K27M Expression Effects Neural Lineage
The importance of histone marks, H3K4me3 and H3K27me3, at specific stages of
neural lineage progression are known to have direct regulatory effects on neural
development [106, 166]. Studies have shown that with further neural lineage restriction
the likelihood of developing brain tumors decreases based on the cell of origin [97, 98].
Therefore, we examined the link between the potential cell of origin and the histone
methylation marks present at critical genes that may be responsible glioma formation in
our model. Wieland Huttner’s group had previously classified a range of cortical cell
populations, including NECs, apical and basal radial glial progenitors/neurons, and
neurons, through early development (E9.5-E14.5) for cell type-specific histone
methylation patterns, like bivalent gene promoters [106]. They found genes related to
axon guidance and neural function that were bivalent in the NEC state were then turned
on (H3K4me3+ and H3K27me3-) throughout lineage progression and into the neuronal
state. Based on the DNA damage data for embryonic cortical cell layers with Brca2- and
Lig4-deficiency (Figure 4-10) we chose three of these cell populations, NECs, apical
radial glia committed to a neurogenic lineage (aRG-N), and neurons to compare tumor
expression data. The DNA damage spatial difference is important when defining the
unique cellular populations effected. NEC and aRG-Ns are found in the lower VZ where
the majority of the Brca2-deficient damage was discovered. While the upper cortex in the
CP and IZ contains more mature and differentiated neurons where the primary amount of
Lig4-deficient damage was identified. Because (Brca2;p53;H3K27M)Emx1-cre and
(Lig4;p53;H3K27M)Emx1-cre displayed the most drastic phenotypes, both in terms of DNA
damage and gliomagenesis, and had the greatest differences between bivalent gene
promoter patterns we chose to focus the analysis on these two cohorts. We found that
(Lig4;p53;H3K27M)Emx1-cre had significantly higher overall number of genes (~175)
marked as bivalent at promoter regions through cortical development than
(Brca2;p53;H3K27M)Emx1-cre mice (~5 genes). Moreover, (Lig4;p53;H3K27M)Emx1-cre had
a high number of genes associated with aRG-Ns (140) and neurons (170) marked only
with the gene activation associated mark, H3K4me3, which correlates with the overall
increased gene expression we observed in these tumors. Both DSBR-deficient H3K27M
mice displayed decreased bivalency through neural lineage progression which aligns with
the current evidence suggesting genes that are bivalent in NECs are primed for
expression and lose bivalency as they commit to cell states through differentiation and
maturation.
One of the most interesting findings from this data set comparison was that
(Brca2;p53;H3K27M)Emx1-cre mice had fewer total methylation marks in any category or
cell type (~5) (Figure 4-10). This is probably a direct result of the DNA damage induced
on the earlier cortical progenitor cell population that (Brca2;p53;H3K27M)Emx1-cre mice
display. The increased amount of genome instability in the apical progenitors reprograms
and alters the pluripotency potential by decreasing bivalency within these cells that
eventually transform into tumor cells. Furthermore, a recent study showed that DNA
damage repair plays an essential role in cancer cell reprogramming that can go as far as
reactivation of pluripotency genes [275], which suggest this process could be disrupted
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by DSBR-deficiency. Alternatively, Lig4-deficiency directly effects mature neurons that
are already lineage committed and these cells contain genes with bivalent promoters that
are more related to later neural development and tumorigenesis. Some of the most
upregulated genes we identified were reflective of these pathways, including Pdgfβ, Sox9,
and Syn2. Overexpression of Pdgfβ in particular has been used in other mouse models to
drive gliomagenesis [157]. Interestingly, through this analysis we were able to identify
Cdkn2a as the only gene marked with H3K4me3 throughout all neural lineage cell types
as downregulated in the (Lig4;p53;H3K27M)Emx1-cre tumors, indicating the probable early
inactivation of this important tumor suppressor gene. The association of specific
methylation marks on genes linked to neural development and tumorigenesis helps to
provide some understanding of how mechanistically a combination of tumor related
mutations, including Brca2, Lig4, p53 and H3K27M, may be cooperating in the earliest
stages of corticogenesis to impose additional aberrations that ultimately cause
gliomagenesis. Although this direct comparison of two different gene expression datasets
from mouse tumors and mouse embryonic neural cells may not be the most ideal
assessment, it nonetheless still gives insight into the potential mechanisms of
gliomagenesis and opens up the possibility for future embryonic and post-natal cell
sequencing experiments.
Closing Remarks
The research presented in my dissertation presents a new pHGG mouse model and
examines the cooperation between genome instability and oncohistone mutations in
gliomagenesis. Our data show that inhibition of DSBR by either Brca2-deficiency (HR)
or Lig4-deficiency (NHEJ) in combination with p53 inactivation results in gliomas
resulting from elevated genome instability during embryogenesis. Furthermore, we found
that H3K27M expression promotes genome instability and accelerates cortical
gliomagenesis, in the context of genome damage, from embryonic progenitors or
neurons. We show that this is through upregulation of genes normally controlled by
bivalent promoter post-translational modifications, like H3K27me3 and H3K4me3,
which results in transcriptional alterations in genes important for both neural
development and tumorigenesis. We suggest this occurs in specific populations of
cortical cells that are more susceptible to DNA damage and transformations that may
cause additional critical mutations during a limited timeframe of early cortical
development which eventually result in pHGGs. Knowing that epigenetic regulation is
tightly connected with neural development and differentiation, we propose that it is likely
the specific genes affected by H3K27M expression may involve the developmental stage
and cell state from which the glioma initiates. We believe this may contribute to the
reduced heterogeneity in glioma expression signatures we found with H3K27M in
addition to either HR- or NHEJ-deficiency. Ultimately this work underscores the power
of engineered mouse models as an approach to further understand the impact of genome
instability leading to gliomagenesis. Furthermore, I hope these and other physiologically
relevant high-grade gliomagenesis models will be useful for future mechanistic and
preclinical therapy studies to develop effective treatments for these devastating diseases.
A summary of these studies is presented as a working model in (Figure 5-1).
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Figure 5-1. Schematic of DSBR and H3K27M importance during early cortical
development.
Stem and progenitor cells initiate corticogenesis around E10 in which they undergo a
process of interkinetic nuclear migration where the nuclei of these cells (NEC) or radial
glia (RG) cells occupy different positions along the apical-basal SVZ axis depending on
the phase of the cell cycle. These are what we consider the “immature” cell population. In
these cells DSBR is predominantly performed by HR (Brca2). H3K27M and the loss of
bivalent promoters are also critical in these early progenitors. As cells progress through
neural lineage they use RGs as scaffolding to migrate away from the apical surface and
become differentiated/mature cortical neurons. Radial migration can be broken into four
phases by unique cell types. Newborn neurons leave the proliferative areas (I) and reach
the SVZ/IZ, where they attain a multipolar morphology (II). After pausing in the SVZ/IZ,
cells migrate toward the CP, using kinetic energy (III). At the end of their migration,
cortical neurons switch to translocation of the soma (IV). During the transition to
differentiation and maturation the cells exit the cell cycle and therefore rely on NHEJ
(Lig4) for DSBR. The amount of DNA damage accumulation is primarily defined to the
layers in which the cells are either HR- or NHEJ-deficient. When H3K27M is present it
tends to effect more of the earlier cortical progenitors in the deep layers. The loss of
H3K27me3 (repressive) on the bivalent state drives increased gene expression with only
H3K4me3 (active) present. In addition, the active chromatin state is a more open
structure which is more exposed to DNA damage resulting in increased genome
instability. The combination of the H3K27M effects leads to accelerated gliomagenesis
and decreased survival. All mutations induced with Emx1-cre at E9.5. E12-E18 is a
robust period of cortical development. Red stars indicated timepoints of embryonic
analysis (E12.5/E15.5). MZ, marginal zone; CP, cortical plate; IZ, intermediate zone;
SVZ, subventricular zone; VZ, ventricular zone.
Modified with open access permission. Azzarelli, R., F. Guillemot, and E. Pacary,
Function and regulation of Rnd proteins in cortical projection neuron migration. Front
Neurosci, 2015. 9: p. 19.
Modified minimally from Cancer Cell, Vol:35/Issue:1, Larson, J.D., et al., Histone H3.3
K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in
Bivalent Gene Expression., p. 140-155., Copyright (2019), with permission from
Elsevier.
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